A Phase 3 interventional study of Guselkumab and Placebo in Arthritis, Psoriatic, sponsored by Janssen Research & Development, LLC. Completed at 138 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing guselkumab in Arthritis, Psoriatic — 5 open to participants now, 8 under way, 3 of them phase 3. guselkumab · Arthritis, Psoriatic.
Among the 14 studies testing guselkumab in Arthritis, Psoriatic, this one is the 2nd largest by enrollment, is one of 2 that started in 2017, is one of 7 in phase 3, and was the 2nd registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
Browse Arthritis, Psoriatic studies →5 of the 14 studies testing guselkumab in Arthritis, Psoriatic are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
NYU Langone Health · Sites in United States
Ages 18+
Johnson & Johnson Private Limited · Sites in India
Ages 18+
University of California, San Diego · Sites in United States
Janssen Research & Development, LLC · Sites in United States, Argentina, Australia and 15 more countries
Ages 3+
By country, each count listing its studies:
guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 741 is above the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 173 across the 14 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 14 have an industry lead sponsor. The 6 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
37 studies in Arthritis, Psoriatic by Johnson & Johnson: 5 open now, 13 under way, 5 of them phase 3. Of 23 finished, 13 (57%) have results posted.
Among the 37 studies in Arthritis, Psoriatic by Johnson & Johnson, this one is the 3rd largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2017, is one of 15 in phase 3, and was the 18th registered.
Johnson & Johnson’s Arthritis, Psoriatic studies by the year they started, since 2002.
4 of the studies testing guselkumab in Arthritis, Psoriatic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04929210Janssen Research & Development, LLCA Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease | 2027-04-01 |
| NCT07141004Johnson & Johnson Private LimitedA Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA) | 2027-06-05 |
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
| NCT06586281University of California, San DiegoElucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 14 studies testing guselkumab in Arthritis, Psoriatic, from their registry updates:
Among Johnson & Johnson’s 37 in Arthritis, Psoriatic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
This is a study of guselkumab in participants with active PsA who are biologically naive and have had inadequate response to standard therapies. It will evaluate the clinical efficacy of guselkumab in the reduction of signs and symptoms, structural damage inhibition and the safety profile of guselkumab in the treatment of PsA. The study will consist of a screening phase (up to 6 weeks), a blinded treatment phase (approximately 100 weeks) including a placebo controlled period from Week 0 to Week 24 and an active treatment period from Week 24 to Week 100 and a safety follow-up phase of 12 weeks after the last administration of study agent. Efficacy, health economics, safety, pharmacokinetics, immunogenicity, biomarker and pharmacogenomics evaluations will be performed in the study at defined schedule.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive subcutaneous (SC) guselkumab 100 milligram (mg) once every 4 weeks (q4w) from Week 0 through Week 100.
Drug: Guselkumab
Participants will receive SC guselkumab 100 mg at Weeks 0 and 4 then once every 8 weeks (q8w) (Weeks 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, and 100) and placebo injections at other visits (Weeks 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, and 96) to maintain the blind.
Drug: Guselkumab · Drug: Placebo
Participants will receive SC placebo q4w from Week 0 to Week 20 and will cross over at Week 24 to receive SC guselkumab 100 mg q4w from Week 24 through Week 100.
Drug: Guselkumab · Drug: Placebo
Participants will receive 100 mg of guselkumab as a sterile liquid for SC injection.
Also known as: CNTO 1959
Participants will receive matching placebo as SC injection.
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24
ACR 20 response: \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP. Treatment Failure (TF) criteria- discontinued study drug, initiated/increased dose of non-biologic disease-modifying antirheumatic drugs (DMARDs) or oral corticosteroids, initiated prohibited psoriatic arthritis treatment.
Time frame: Week 24
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.
Time frame: Baseline and Week 24
Percentage of Participants Who Achieved an ACR 50 Response at Week 24
ACR 50 response was defined as greater than or equal to (\>=)50 percent (%) improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and C-Reactive Protein (CRP).
Time frame: Week 24
Percentage of Participants Who Achieved Psoriasis Response With IGA Score of 0 (Cleared) or 1 (Minimal) and >=2 Grade Reduction From Baseline at Week 24 Among Participants With >=3% BSA Psoriatic Involvement and IGA Score of >=2 (Mild) at Baseline
A psoriasis Investigator's Global Assessment (IGA) response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>=2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Time frame: Week 24
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16
ACR 20 response was defined as \>= 20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
Time frame: Week 16
Change From Baseline in Modified Van Der Heijde-Sharp (vdH-S) Score at Week 24
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Time frame: Baseline and Week 24
Percentage of Participants With Resolution of Enthesitis at Week 24 Among the Participants With Enthesitis at Baseline
Enthesitis was assessed using the Leeds Enthesitis Index (LEI), a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.
Time frame: Week 24
Percentage of Participants With Resolution of Dactylitis at Week 24 Among the Participants With Dactylitis at Baseline
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.
Time frame: Week 24
Change From Baseline in Enthesitis Score (Based on LEI) at Week 24 Among the Participants With Enthesitis at Baseline
Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.
Time frame: Baseline and Week 24
Change From Baseline in Dactylitis Scores at Week 24 Among the Participants With Dactylitis at Baseline
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement of dactylitis. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.
Time frame: Baseline and Week 24
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline and Week 24
Change From Baseline in Disease Activity Score (DAS28) (C-reactive Protein [CRP]) Score at Week 24
The Disease Activity Index Score (DAS28) based on C-Reactive Protein (CRP) is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.
Time frame: Baseline and Week 24
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) at Week 24
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline and Week 24
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 16
ACR 50 response was defined as \>= 50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
Time frame: Week 16
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 70 Response at Week 24
ACR 70 response was defined as \>= 70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
Time frame: Week 24
Percentage of Participants Who Achieved ACR 20 Response Through Week 24
ACR 20 response was defined as \>= 20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants Who Achieved ACR 50 Response Through Week 24
ACR 50 response was defined as \>= 50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants Who Achieved ACR 70 Response Through Week 24
ACR 70 response was defined as \>= 70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24
Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24
ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment (PtGA) of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment (PGA) of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (milligram/deciliter \[mg/dL\]).
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24
HAQ-DI score assess functional status of participant. It is a 20 question instrument that assess the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative changes from baseline indicate improvement of physical function.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline
HAQ-DI score assess functional status of participant. It is a 20 question instrument that assess the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.
Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS 28 (CRP) response criteria was defined as follows: Good response: \<=3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder is defined as achieving a good or moderate DAS28 response at a specific visit.
Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS 28 (CRP) remission was defined as DAS 28 (CRP) value \<2.6 at the analysis visit.
Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24
Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24
The modified PsARC response was defined as improvement in at least 2 of the four criteria: \>=30% decrease in swollen joint count, \>=30% decrease in tender joint count, \>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) on a VAS (0-100 mm, 0=excellent and 100= poor), \>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.
Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants With Resolution of Enthesitis Through Week 24 Among the Participants With Enthesitis at Baseline
Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.
Time frame: Weeks 2, 4, 8, 16 and 24
Percentage of Participants With Resolution of Dactylitis Through Week 24 Among the Participants With Dactylitis at Baseline
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.
Time frame: Weeks 2, 4, 8, 16 and 24
Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 2, 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline
Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.
Time frame: Baseline, Weeks 2, 4, 8, 16 and 24
Change From Baseline in Dactylitis Scores at Weeks 2, 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement of dactylitis.
Time frame: Baseline, Weeks 2, 4, 8, 16 and 24
Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 8, 16 and 24
PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.
Time frame: Baseline, Weeks 8, 16 and 24
Change From Baseline in Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Composite Score (GRACE) at Weeks 16 and 24
GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\*HAQ-DI\]-\[0.234\*SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0-100, higher scores= better quality of life) and SF-MCS (score ranges from 0-100, higher scores= better quality of life). Total score is from 0-10, lower score=better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.
Time frame: Baseline, Weeks 16 and 24
Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Work Time Missed) at Weeks 16 and 24
Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
Time frame: Baseline, Weeks 16 and 24
Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Impairment While Working) at Weeks 16 and 24
Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
Time frame: Baseline, Weeks 16 and 24
Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Overall Work Impairment) at Weeks 16 and 24
Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAi-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
Time frame: Baseline, Weeks 16 and 24
Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Activity Impairment Outside of Work ) at Weeks 16 and 24
Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
Time frame: Baseline, Weeks 16 and 24
Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Week 16 and 24
The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity.
Time frame: Baseline, Weeks 16 and 24
Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24
DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL, value \<lower limit of quantification \[LLOQ\] is considered equal to half of the value of LLOQ for numerical calculations), patient assessment of pain (0-10cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants Who Achieved Minimal Disease Activity (MDA) Criteria Through Week 24
MDA is a measure that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved the PsA MDA at a visit if the participant has fulfilled at least 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI index score \<= 1).
Time frame: Weeks 16 and 24
Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.
Time frame: Weeks 8, 16 and 24
Percentage of Participants Who Achieved PASI 75 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 75 response: \>=75% improvement in PASI score from baseline.
Time frame: Weeks 16 and 24
Percentage of Participants Who Achieved PASI 90 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 90 response: \>=90% improvement in PASI score from baseline.
Time frame: Weeks 16 and 24
Percentage of Participants Who Achieved PASI 100 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 100 response: 100% improvement in PASI score from baseline.
Time frame: Weeks 16 and 24
Percentage of Participants With an IGA Score of 0 (Cleared) Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>=2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Time frame: Weeks 16 and 24
Change From Baseline in PASI Score at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative change from baseline indicates improvement of psoriasis.
Time frame: Baseline, Weeks 16 and 24
Percentage of Participants Who Achieved a DLQI Score of 0 or 1 Through Week 24 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. A DLQI score of 0 or 1 indicates psoriasis had no effect at all on patient's life.
Time frame: Weeks 8, 16, 24
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score Through Week 24 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. An improvement of 5 points was considered clinically meaningful.
Time frame: Weeks 8, 16, 24
Change From Baseline in DLQI Score at Weeks 8, 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. Negative changes from baseline indicate improvement of life quality impacted by psoriasis.
Time frame: Baseline, Weeks 8, 16 and 24
Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in swollen joint count (SJC) (66 joints) + tender joint count (TJC) (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.
Time frame: Weeks 16 and 24
Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.
Time frame: Weeks 16 and 24
Change From Baseline in Modified vdH-S Erosion Score at Week 24
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Time frame: Baseline and Week 24
Change From Baseline in Modified vdH-S Joint Space Narrowing (JSN) Score at Week 24
The modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). The JSN score is the total JSN score in 40 joints of the two hands and 12 joints of the 2 feet. Each joint is scored from 0 to 4 with 0 indicating no JSN, and 4 indicating a complete loss of joint space, bony ankylosis, or complete luxation, for a maximum JSN score of 208. Higher score indicates more severe joint space narrowing. A positive change from baseline in the modified vdH-S JSN score indicates progression of joint space narrowing.
Time frame: Baseline and Week 24
Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24
Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand (Hand erosion score) scored according to 0 (no erosion) to 5 (complete collapse of bone) for a maximum hand erosion score of 200, and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum foot erosion score of 120. Higher scores indicate more joint damage. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum Hand JSN score of 160 and maximum Foot JSN score of 48. Higher scores indicate more joint damage. Hand Score (sum of Hand Erosion Score and Hand JSN Score) scored as 0-360 and Foot score (sum of foot erosion score and foot JSN score) scored as 0-168. Higher scores indicate more joint damage.
Time frame: Baseline and Week 24
Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 24
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Time frame: Week 24
Percentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 24
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Time frame: Week 24
Percentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S JSN Score at Week 24
The modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). The JSN score is the sum of JSN score in 40 joints of the two hands and 12 joints of the 2 feet. Each joint is scored from 0 - 4 with 0 indicating no JSN, and 4 indicating a complete loss of joint space, bony ankylosis, or complete luxation, for a maximum JSN score of 208. Higher score indicates more severe joint space narrowing. Change from baseline in the modified vdH-S JSN score \<=0 (assessed by both readers) or \<=0.5 (assessed by at least one reader) was considered as no progression of JSN.
Time frame: Week 24
Percentage of Participants Without Radiographic Progression (Based on the Smallest Detectable Change [SDC]) From Baseline at Week 24
Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic progression was defined as change from baseline in the modified vdH-S score \<=SDC of 2.18.
Time frame: Week 24
Percentage of Participants Without Radiographic Joint Erosion Progression (Based on SDC) From Baseline at Week 24
Modified vdH-S score is sum of erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC defined as the cut-off above which changes can be detected beyond measurement error. Without radiographic joint erosion progression was defined as change from baseline in modified vdH-S erosion score \<=SDC of 1.83.
Time frame: Week 24
Percentage of Participants Without Radiographic JSN Progression (Based on the SDC) From Baseline at Week 24
The modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). The JSN score is the sum of JSN score in 40 joints of the two hands and 12 joints of the 2 feet. Each joint is scored from 0 - 4 with 0 indicating no JSN, and 4 indicating a complete loss of joint space, bony ankylosis, or complete luxation, for a maximum JSN score of 208. Higher score indicates more severe joint space narrowing. The smallest detectable change (SDC) was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic JSN progression was defined as change from baseline in the modified vdH-S JSN score \<=SDC of 1.11.
Time frame: Week 24
Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 24
Pencil in Cup or Gross Osteolytis Deformities are radiographic features specific for psoriatic arthritis.
Time frame: Baseline and Week 24
Change From Baseline in SF-36 PCS Score at Weeks 8, 16 and 24
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline, Weeks 8, 16 and 24
Change From Baseline in SF-36 MCS Score at Weeks 8, 16 and 24
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline, Weeks 8, 16 and 24
Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline and Weeks 8, 16 and 24
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score Through Week 24
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
Time frame: Week 8, 16 and 24
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score Through Week 24
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
Time frame: Week 8, 16 and 24
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 8, 16, and 24
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
Time frame: Baseline, Weeks 8, 16 and 24
Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement Through Week 24
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
Time frame: Weeks 8, 16 and 24
Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Weeks 16 and 24: EQ-VAS
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a vertical line VAS with scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). A higher score indicates better health and positive changes from baseline indicate improvement of health status
Time frame: Baseline, Weeks 16 and 24
Change From Baseline in EQ-5D-5L at Weeks 16 and 24: EQ-5D Index
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a weighted summary index (EQ-5D index), which ranges from 0 (dead) to 1.00 (full health). A higher score indicates better health and positive changes from baseline indicate improvement of health.
Time frame: Baseline, Weeks 16 and 24
Percentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52
ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Time frame: Weeks 24, 28, 36, 44 and 52
Percentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52
ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Time frame: Weeks 24, 28, 36, 44 and 52
Percentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52
ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Time frame: Weeks 24, 28, 36, 44 and 52
ACR Components at Weeks 24, 28, 36, 44 and 52
ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).
Time frame: Weeks 24, 28, 36, 44 and 52
Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52
ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).
Time frame: Baseline, Weeks 24, 28, 36, 44 and 52
Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52
ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).
Time frame: Baseline, Weeks 24, 28, 36, 44 and 52
Percentage of Participants Who Maintained an ACR 20 Response at Week 52 Among Participants Who Achieved an ACR 20 Response at Week 24
ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Time frame: Week 52
Percentage of Participants Who Maintained an ACR 50 Response at Week 52 Among Participants Who Achieved an ACR 50 Response at Week 24
ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Time frame: Week 52
Percentage of Participants Who Maintained an ACR 70 Response at Week 52 Among Participants Who Achieved an ACR 70 Response at Week 24
ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 millimeters \[mm\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Time frame: Week 52
Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.
Time frame: Baseline, Weeks 24, 28, 36, 44 and 52
Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.
Time frame: Weeks 24, 28, 36, 44 and 52
Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 52 Among Participants Who Achieved a HAQ-DI Response at Week 24
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.
Time frame: Week 52
Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS28 (CRP) response criteria was defined as follows: Good response: \<=3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder was defined as achieving a good or moderate DAS28 response at a specific visit.
Time frame: Weeks 24, 28, 36, 44 and 52
Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS28 (CRP) remission was defined as DAS28 (CRP) value \<2.6 at the analysis visit.
Time frame: Weeks 24, 28, 36, 44 and 52
Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.
Time frame: Baseline, Weeks 24, 28, 36, 44 and 52
Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52
The modified PsARC response was defined as improvement in at least 2 of the four criteria: \>=30% decrease in swollen joint count, \>=30% decrease in tender joint count, \>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) on a VAS (0-100 mm, 0=excellent and 100= poor), \>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.
Time frame: Weeks 24, 28, 36, 44 and 52
Percentage of Participants With Resolution of Enthesitis at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline
Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.
Time frame: Weeks 24 and 52
Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline
Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.
Time frame: Baseline, Weeks 24 and 52
Percentage of Participants With Resolution of Dactylitis at Weeks 24 and 52 Among Participants With Dactylitis at Baseline
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.
Time frame: Weeks 24 and 52
Change From Baseline in Dactylitis Score at Weeks 24 and 52 Among the Participants With Dactylitis at Baseline
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. A higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement in dactylitis.
Time frame: Baseline, Weeks 24 and 52
Change From Baseline in Psoriatic Arthritis Disease Activity (PASDAS) Score at Weeks 24 and 52
PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.
Time frame: Baseline, Weeks 24 and 52
Percentage of Participants With Low or Very Low Disease Activity Based on Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 24 and 52
PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.
Time frame: Weeks 24 and 52
Change From Baseline in Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52
GRACE index is a composite PsA disease activity score converted from AMDF, which was derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100= poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL =25.355 + \[2.367\*HAQ-DI\] - \[0.234\*SF-PCS\] - \[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0 to 100, higher scores= better quality of life) and SF-MCS (score ranges from 0 to 100, higher scores= better quality of life). The total score is from 0-10, where lower score indicates better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.
Time frame: Baseline, Weeks 24 and 52
Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52
GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), PtGA of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), PtGA of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\*HAQ-DI\]-\[0.234\*SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score range= 0-100, higher scores= better quality of life) and SF-MCS (score range=0-100, higher scores= better quality of life). Total score is 0-10, lower score=better response. Higher score= more active disease activity. Negative change from baseline indicates improvement of PsA disease activity. GRACE low disease activity is GRACE score \<=2.3 at the analysis visit.
Time frame: Weeks 24 and 52
Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52
DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL), patient assessment of pain (0-10cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.
Time frame: Baseline, Weeks 24, 28, 36, 44 and 52
Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52
The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity.
Time frame: Baseline, Weeks 24 and 52
Percentage of Participants With Low Disease Activity Based on Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52
The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. mCPDAI low disease activity is defined as mCPDAI score \<=3.2 at the analysis visit.
Time frame: Weeks 24 and 52
Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 24 and 52
MDA is a measure that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved the PsA MDA at a visit if the participant has fulfilled at least 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI index score \<= 1).
Time frame: Weeks 24 and 52
Percentage of Participants With Very Low Disease Activity (VLDA) at Weeks 24 and 52
A measurement that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved VLDA at a visit if the participant fulfilled all 7 criteria (tender joint count \<=1; swollen joint count \<=1; PASI \<=1; patient pain VAS score of \<=15; patient global disease activity VAS \[arthritis and psoriasis\] score of \<=20; Health Assessment Questionnaire (HAQ) score \<=0.5; and tender entheseal points \<=1) at that visit.
Time frame: Weeks 24 and 52
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Weeks 24 and 52 Among Participants With Spondylitis and Peripheral Arthritis at Baseline
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.
Time frame: Baseline, Weeks 24 and 52
Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.
Time frame: Weeks 24 and 52
Change From Baseline in PASI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative change from baseline indicates improvement of psoriasis.
Time frame: Baseline, Weeks 24 and 52
Percentage of Participants Who Achieved PASI 50 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 50 response: \>=50% improvement in PASI score from baseline.
Time frame: Weeks 24 and 52
Percentage of Participants Who Achieved PASI 75 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline.
Time frame: Weeks 24 and 52
Percentage of Participants Who Achieved PASI 90 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 90 response: \>=90% improvement in PASI score from baseline.
Time frame: Weeks 24 and 52
Percentage of Participants Who Achieved PASI 100 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 100 response: 100% improvement in PASI score from baseline.
Time frame: Weeks 24 and 52
Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in SJC (66 joints)+TJC (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.
Time frame: Weeks 24 and 52
Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.
Time frame: Weeks 24 and 52
Percentage of Participants Who Achieved an IGA Response at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Time frame: Weeks 24 and 52
Percentage of Participants Who Achieved an IGA Score of 0 (Cleared) at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Time frame: Weeks 24 and 52
Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 24 and 52 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. A DLQI score of 0 or 1 indicates psoriasis had no effect at all on patient's life.
Time frame: Weeks 24 and 52
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. An improvement of 5 points was considered clinically meaningful.
Time frame: Weeks 24 and 52
Change From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. Negative changes from baseline indicate improvement of life quality impacted by psoriasis.
Time frame: Baseline, Weeks 24 and 52
Change From Baseline in Modified vdH-S Score at Week 52
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Time frame: Baseline and Week 52
Change in Total Modified vdH-S Score From Week 24 to Week 52
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage.
Time frame: From Week 24 to Week 52
Change From Baseline in Modified vdH-S Erosion Score at Week 52
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Time frame: Baseline and Week 52
Change in Modified vdH-S Erosion Score From Week 24 to Week 52
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage.
Time frame: From Week 24 to Week 52
Change From Baseline in Modified vdH-S JSN Score at Week 52
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Time frame: Baseline and Week 52
Change in Modified vdH-S JSN Score From Week 24 to Week 52
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage.
Time frame: From Week 24 to Week 52
Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52
Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand (Hand erosion score) scored according to 0 (no erosion) to 5 (complete collapse of bone) for a maximum hand erosion score of 200, and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum foot erosion score of 120. Higher scores indicate more joint damage. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum Hand JSN score of 160 and maximum Foot JSN score of 48. Higher scores indicate more joint damage. Hand Score (sum of Hand Erosion Score and Hand JSN Score) scored as 0-360 and Foot score (sum of foot erosion score and foot JSN score) scored as 0-168. Higher scores indicate more joint damage.
Time frame: Baseline and Week 52
Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 52
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Time frame: Week 52
Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 52
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Time frame: Week 52
Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S JSN Score at Week 52
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Time frame: Week 52
Percentage of Participants Without Radiographic Progression Based on the (SDC) From Baseline at Week 52
Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic progression was defined as change from baseline in the modified vdH-S score \<=SDC of 2.39.
Time frame: Week 52
Percentage of Participants Without Radiographic Joint Erosion Progression Based on (SDC) From Baseline at Week 52
Modified vdH-S score is sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic joint erosion progression was defined as change from baseline in modified vdH-S erosion score \<=SDC of 2.22.
Time frame: Week 52
Percentage of Participants Without Radiographic JSN Progression Based on (SDC) From Baseline at Week 52
Modified vdH-S score is sum of erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as cut-off above which changes can be detected beyond measurement error. Without radiographic JSN progression was defined as change from baseline in modified vdH-S JSN score \<=SDC of 1.02.
Time frame: Week 52
Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 52
Percentage of Participants with Pencil in cup or Gross Osteolysis Deformities were reported. Pencil in Cup or Gross Osteolytis Deformities are radiographic features specific for psoriatic arthritis.
Time frame: Baseline and Week 52
Change From Baseline in SF-36 PCS Score at Weeks 24 and 52
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline, Weeks 24 and 52
Change From Baseline in SF-36 MCS Score at Weeks 24 and 52
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline, Weeks 24 and 52
Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline, Weeks 24 and 52
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 24 and 52
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
Time frame: Weeks 24 and 52
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 24 and 52
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
Time frame: Weeks 24 and 52
Change From Baseline in FACIT-Fatigue Score at Weeks 24 and 52
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
Time frame: Baseline, Weeks 24 and 52
Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement at Weeks 24 and 52
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
Time frame: Weeks 24 and 52
Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-VAS
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a vertical line VAS with scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). A higher score indicates better health and positive changes from baseline indicate improvement of health status.
Time frame: Baseline, Weeks 24 and 52
Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-5D Index
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a weighted summary index (EQ-5D index), which ranges from 0 (dead) to 1.00 (full health). A higher score indicates better health and positive changes from baseline indicate improvement of health.
Time frame: Baseline, Weeks 24 and 52
Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire Scores (Percent Work Time Missed) at Weeks 24 and 52
Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
Time frame: Baseline, Weeks 24 and 52
Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 24 and 52
Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
Time frame: Baseline, Weeks 24 and 52
Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 24 and 52
Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
Time frame: Baseline, Weeks 24 and 52
Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) at Weeks 24 and 52
Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
Time frame: Baseline, Weeks 24 and 52
Percentage of Participants Who Achieved ACR 20 Response at Weeks 52, 68, 76, 84 and 100
ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Time frame: Weeks 52, 68, 76, 84 and 100
Percentage of Participants Who Achieved ACR 50 Response at Weeks 52, 68, 76, 84 and 100
ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Time frame: Weeks 52, 68, 76, 84 and 100
Percentage of Participants Who Achieved ACR 70 Response at Weeks 52, 68, 76, 84 and 100
ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Time frame: Weeks 52, 68, 76, 84 and 100
ACR Components at Weeks 52, 68, 76, 84 and 100
ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).
Time frame: Weeks 52, 68, 76, 84 and 100
Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100
ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).
Time frame: Baseline, Weeks 52, 68, 76, 84 and 100
Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100
ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).
Time frame: Baseline, Weeks 52, 68, 76, 84 and 100
Percentage of Participants Who Maintained an ACR 20 Response at Week 100 Among Participants Who Achieved an ACR 20 Response at Week 52
ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Time frame: Week 100
Percentage of Participants Who Maintained an ACR 50 Response at Week 100 Among Participants Who Achieved an ACR 50 Response at Week 52
ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Time frame: Week 100
Percentage of Participants Who Maintained an ACR 70 Response at Week 100 Among Participants Who Achieved an ACR 70 Response at Week 52
ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 millimeters \[mm\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Time frame: Week 100
Change From Baseline in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.
Time frame: Baseline, Weeks 52, 68, 76, 84 and 100
Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100 Among Participants With HAQ-DI Score >=0.35 at Baseline
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.
Time frame: Weeks 52, 68, 76, 84 and 100
Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 100 Among Participants Who Achieved a HAQ-DI Response at Week 52
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.
Time frame: Week 100
Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 52, 68, 76, 84 and 100
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS28 (CRP) response criteria was defined as follows: Good response: \<=3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder was defined as achieving a good or moderate DAS28 response at a specific visit.
Time frame: Weeks 52, 68, 76, 84 and 100
Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 52, 68, 76, 84 and 100
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS28 (CRP) remission was defined as DAS28 (CRP) value \<2.6 at the analysis visit.
Time frame: Weeks 52, 68, 76, 84 and 100
Change From Baseline in DAS28 (CRP) Score at Weeks 52, 68, 76, 84 and 100
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.
Time frame: Baseline, Weeks 52, 68, 76, 84 and 100
Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 52, 68, 76, 84 and 100
The modified PsARC response was defined as improvement in at least 2 of the four criteria: \>=30% decrease in swollen joint count, \>=30% decrease in tender joint count, \>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) on a VAS (0-100 mm, 0=excellent and 100= poor), \>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.
Time frame: Weeks 52, 68, 76, 84 and 100
Percentage of Participants With Resolution of Enthesitis (LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis (LEI) at Baseline
Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.
Time frame: Weeks 52, 76, and 100
Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis at Baseline
Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.
Time frame: Baseline, Weeks 52, 76 and 100
Percentage of Participants With Resolution of Dactylitis at Weeks 52, 76 and 100 Among Participants With Dactylitis at Baseline
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.
Time frame: Weeks 52, 76 and 100
Change From Baseline in Dactylitis Scores at Weeks 52, 76 and 100 Among the Participants With Dactylitis at Baseline
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement of dactylitis.
Time frame: Baseline, Weeks 52, 76 and 100
Change From Baseline in PASDAS Score at Weeks 52, 76 and 100
PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.
Time frame: Baseline, Weeks 52, 76 and 100
Percentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100
PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining PtGA of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), PGA of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity. Low: PASDAS \<= 3.2; Very low: PASDAS \<= 1.9.
Time frame: Weeks 52, 76 and 100
Change From Baseline in GRAPPA Composite Score (GRACE) at Weeks 52, 76 and 100
GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\*HAQ-DI\]-\[0.234\*SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0-100, higher scores= better quality of life) and SF-MCS (score ranges from 0-100, higher scores= better quality of life). Total score is from 0-10, lower score=better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.
Time frame: Baseline, Weeks 52, 76 and 100
Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 52, 76 and 100
GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), PtGA of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), PtGA of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\*HAQ-DI\]-\[0.234\*SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score range= 0-100, higher scores= better quality of life) and SF-MCS (score range=0-100, higher scores= better quality of life). Total score is 0-10, lower score=better response. Higher score= more active disease activity. Negative change from baseline indicates improvement of PsA disease activity. GRACE low disease activity is GRACE score \<=2.3 at the analysis visit.
Time frame: Weeks 52, 76 and 100
Change From Baseline in DAPSA at Weeks 52, 68, 76, 84 and 100
DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL, value \<lower limit of quantification \[LLOQ\] is considered equal to half of the value of LLOQ for numerical calculations), patient assessment of pain (0-10cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.
Time frame: Baseline, Weeks 52, 68, 76, 84 and 100
Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100
DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL), patient assessment of pain (0-10 cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10 cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. The assessment does not have a score range with an upper or lower bound. Low: DAPSA\<=14; Remission: DAPSA\<=4.
Time frame: Weeks 52, 68, 76, 84 and 100
Change From Baseline in mCPDAI Score at Weeks 52, 76 and 100
The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity.
Time frame: Baseline, Weeks 52, 76 and 100
Percentage of Participants With Low Disease Activity Based on mCPDAI at Weeks 52, 76 and 100
The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. mCPDAI low disease activity is defined as mCPDAI score \<=3.2 at the analysis visit.
Time frame: Weeks 52, 76 and 100
Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 52, 76 and 100
MDA is a measure that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved the PsA MDA at a visit if the participant has fulfilled at least 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI index score \<= 1).
Time frame: Weeks 52, 76 and 100
Percentage of Participants With VLDA at Weeks 52, 76 and 100
A measurement that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved VLDA at a visit if the participant fulfilled all 7 criteria (tender joint count \<=1; swollen joint count \<=1; PASI \<=1; patient pain VAS score of \<=15; patient global disease activity VAS \[arthritis and psoriasis\] score of \<=20; Health Assessment Questionnaire (HAQ) score \<=0.5; and tender entheseal points \<=1) at that visit.
Time frame: Weeks 52, 76 and 100
Change From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among Participants With Spondylitis and Peripheral Arthritis and BASDAI Score>0 at Baseline
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.
Time frame: Baseline, Weeks 52, 76 and 100
Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.
Time frame: Weeks 52, 76 and 100
Change From Baseline in PASI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative change from baseline indicates improvement of psoriasis.
Time frame: Baseline, Weeks 52, 76 and 100
Percentage of Participants Who Achieved PASI 50 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 50 response: \>=50% improvement in PASI score from baseline.
Time frame: Weeks 52, 76 and 100
Percentage of Participants Who Achieved PASI 75 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline.
Time frame: Weeks 52, 76 and 100
Percentage of Participants Who Achieved PASI 90 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 90 response: \>=90% improvement in PASI score from baseline.
Time frame: Weeks 52, 76 and 100
Percentage of Participants Who Achieved PASI 100 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 100 response: 100% improvement in PASI score from baseline.
Time frame: Weeks 52, 76 and 100
Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in swollen joint count (SJC) (66 joints) + tender joint count (TJC) (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.
Time frame: Weeks 52, 76 and 100
Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 52, 76, and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.
Time frame: Weeks 52, 76 and 100
Percentage of Participants With an IGA Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). IGA Response is defined as achieving IGA score of 0 or 1, and \>=2 grade reduction from baseline.
Time frame: Weeks 52, 76 and 100
Percentage of Participants With an IGA Score of 0 (Cleared) at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Time frame: Weeks 52, 76 and 100
Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 52, 76 and 100 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. A DLQI score of 0 or 1 indicates psoriasis had no effect at all on patient's life.
Time frame: Weeks 52, 76 and 100
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. An improvement of 5 points was considered clinically meaningful.
Time frame: Weeks 52, 76 and 100
Change From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. Negative changes from baseline indicate improvement of life quality impacted by psoriasis.
Time frame: Baseline, Weeks 52, 76 and 100
Change in Modified vdH-S Score From Baseline to Week 100
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Time frame: Baseline to Week 100
Change in Total Modified vdH-S Score From Week 52 to Week 100
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage.
Time frame: From Week 52 to Week 100
Change in Modified vdH-s Erosion Score From Baseline to Week 100
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Time frame: Baseline to Week 100
Change in Modified vdH-s Erosion Score From Week 52 to Week 100
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Time frame: From Week 52 to Week 100
Change in Modified vdH-s JSN Score From Baseline to Week 100
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Time frame: Baseline to Week 100
Change in Modified vdH-s JSN Score From Week 52 to Week 100
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Time frame: From Week 52 to Week 100
Change From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)
Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand (Hand erosion score) scored according to 0 (no erosion) to 5 (complete collapse of bone) for a maximum hand erosion score of 200, and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum foot erosion score of 120. Higher scores indicate more joint damage. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum Hand JSN score of 160 and maximum Foot JSN score of 48. Higher scores indicate more joint damage. Hand Score (sum of Hand Erosion Score and Hand JSN Score) scored as 0-360 and Foot score (sum of foot erosion score and foot JSN score) scored as 0-168. Higher scores indicate more joint damage.
Time frame: Baseline to Week 100
Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Score
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Time frame: Baseline to Week 100
Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Erosion Score
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Time frame: Baseline to Week 100
Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S JSN Score
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Time frame: Baseline to Week 100
Percentage of Participants Without Radiographic Modified vdH-S Progression Based on (SDC) From Baseline to Week 100
Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic progression was defined as change from baseline in the modified vdH-S score \<=SDC of 3.46.
Time frame: Baseline to Week 100
Percentage of Participants Without Radiographic Erosion Progression (Based on SDC) From Baseline to Week 100
Modified vdH-S score is sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic erosion progression was defined as change from baseline in the modified vdH-S erosion score \<=SDC of 2.66.
Time frame: Baseline to Week 100
Percentage of Participants Without Radiographic JSN Progression (Based on SDC) From Baseline to Week 100
Modified vdH-S score is sum of erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic JSN progression was defined as change from baseline in the modified vdH-S JSN score \<=SDC of 1.66.
Time frame: Baseline to Week 100
Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline, Weeks 24, 52, and 100
Pencil in Cup or Gross Osteolytis Deformities are radiographic features specific for psoriatic arthritis.
Time frame: Baseline, Weeks 24, 52, and 100
Change From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline, Weeks 52, 76 and 100
Change From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline, Weeks 52, 76 and 100
Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline, Weeks 52, 76 and 100
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
Time frame: Weeks 52, 76 and 100
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
Time frame: Weeks 52, 76 and 100
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 52, 76 and 100
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
Time frame: Baseline, Weeks 52, 76 and 100
Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Weeks 52, 76 and 100
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
Time frame: Weeks 52, 76 and 100
Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-VAS
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a vertical line VAS with scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). A higher score indicates better health and positive changes from baseline indicate improvement of health status.
Time frame: Baseline, Weeks 52, 76 and 100
Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-5D Index
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a weighted summary index (EQ-5D index), which ranges from 0 (dead) to 1.00 (full health). A higher score indicates better health and positive changes from baseline indicate improvement of health.
Time frame: Baseline, Weeks 52, 76 and 100
Change From Baseline in WPAI Scores (Percent Work Time Missed) at Weeks 52, 76 and 100
Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
Time frame: Baseline, Weeks 52, 76 and 100
Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 52, 76 and 100
Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
Time frame: Baseline, Weeks 52, 76 and 100
Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 52, 76 and 100
Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
Time frame: Baseline, Weeks 52, 76 and 100
Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) Weeks 52, 76 and 100
Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
Time frame: Baseline, Weeks 52, 76 and 100
| Milestone | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Started | 246 | 248 | 245 |
| Pooled population: enthesitis assessment | 255 | 230 | 243 |
| Pooled population: dactylitis assessment | 154 | 160 | 159 |
| Completed | 240 | 240 | 236 |
| Not completed | 6 | 8 | 9 |
| Withdrew: Adverse event | 4 | 2 | 6 |
| Withdrew: Lack of efficacy | 0 | 3 | 3 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Other | 1 | 1 | 0 |
| Milestone | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Started | 238 | 240 | 234 |
| Completed | 228 | 234 | 227 |
| Not completed | 10 | 6 | 7 |
| Withdrew: Adverse event | 3 | 0 | 1 |
| Withdrew: Lack of efficacy | 5 | 3 | 4 |
| Withdrew: Withdrawal by subject | 1 | 2 | 1 |
| Withdrew: Pregnancy | 0 | 0 | 1 |
| Withdrew: Other | 1 | 1 | 0 |
| Milestone | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Started | 228 | 232 | 227 |
| Completed | 210 | 223 | 219 |
| Not completed | 18 | 9 | 8 |
| Withdrew: Adverse event | 7 | 5 | 3 |
| Withdrew: Lack of efficacy | 1 | 1 | 3 |
| Withdrew: Withdrawal by subject | 5 | 2 | 1 |
| Withdrew: Pregnancy | 0 | 0 | 1 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Other | 4 | 1 | 0 |
ACR 20 response: \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP. Treatment Failure (TF) criteria- discontinued study drug, initiated/increased dose of non-biologic disease-modifying antirheumatic drugs (DMARDs) or oral corticosteroids, initiated prohibited psoriatic arthritis treatment.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 | 32.9 | 64.1 | 63.7 |
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24 | -0.1300 (-0.1912 to -0.0687) | -0.3672 (-0.4282 to -0.3062) | -0.4004 (-0.4617 to -0.3390) |
ACR 50 response was defined as greater than or equal to (\>=)50 percent (%) improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and C-Reactive Protein (CRP).
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Who Achieved an ACR 50 Response at Week 24 | 14.2 | 31.5 | 33.1 |
A psoriasis Investigator's Global Assessment (IGA) response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>=2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Who Achieved Psoriasis Response With IGA Score of 0 (Cleared) or 1 (Minimal) and >=2 Grade Reduction From Baseline at Week 24 Among Participants With >=3% BSA Psoriatic Involvement and IGA Score of >=2 (Mild) at Baseline | 19.1 | 70.5 | 68.5 |
ACR 20 response was defined as \>= 20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16 | 33.7 | 55.2 | 55.9 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change From Baseline in Modified Van Der Heijde-Sharp (vdH-S) Score at Week 24 | 0.95 (0.61 to 1.29) | 0.52 (0.18 to 0.86) | 0.29 (-0.05 to 0.63) |
Enthesitis was assessed using the Leeds Enthesitis Index (LEI), a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants With Resolution of Enthesitis at Week 24 Among the Participants With Enthesitis at Baseline | 29.4 | 49.6 | 44.9 |
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants With Resolution of Dactylitis at Week 24 Among the Participants With Dactylitis at Baseline | 42.2 | 59.4 | 63.5 |
Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change From Baseline in Enthesitis Score (Based on LEI) at Week 24 Among the Participants With Enthesitis at Baseline | -1.02 (-1.22 to -0.82) | -1.52 (-1.73 to -1.31) | -1.59 (-1.79 to -1.38) |
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement of dactylitis. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change From Baseline in Dactylitis Scores at Week 24 Among the Participants With Dactylitis at Baseline | -4.21 (-5.05 to -3.36) | -6.10 (-6.92 to -5.27) | -5.97 (-6.84 to -5.11) |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24 | 3.42 (2.53 to 4.32) | 7.39 (6.50 to 8.29) | 7.04 (6.14 to 7.94) |
The Disease Activity Index Score (DAS28) based on C-Reactive Protein (CRP) is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change From Baseline in Disease Activity Score (DAS28) (C-reactive Protein [CRP]) Score at Week 24 | -0.97 (-1.11 to -0.84) | -1.59 (-1.72 to -1.45) | -1.62 (-1.76 to -1.49) |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) at Week 24 | 2.14 (1.07 to 3.22) | 4.17 (3.10 to 5.23) | 4.22 (3.14 to 5.29) |
ACR 50 response was defined as \>= 50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 16 | 9.3 | 28.6 | 20.8 |
ACR 70 response was defined as \>= 70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 70 Response at Week 24 | 4.1 | 18.5 | 13.1 |
ACR 20 response was defined as \>= 20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 2 | 8.1 | 10.1 | 10.6 |
| Week 4 | 11.8 | 19.8 | 21.6 |
| Week 8 | 17.5 | 39.1 | 40.0 |
| Week 12 | 26.4 | 49.6 | 51.0 |
| Week 16 | 33.7 | 55.2 | 55.9 |
| Week 20 | 29.7 | 62.9 | 58.8 |
| Week 24 | 32.9 | 64.1 | 63.7 |
ACR 50 response was defined as \>= 50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 2 | 0.4 | 1.6 | 0.4 |
| Week 4 | 1.2 | 4.0 | 3.3 |
| Week 8 | 4.1 | 10.1 | 11.0 |
| Week 12 | 6.1 | 19.0 | 16.7 |
| Week 16 | 9.3 | 28.6 | 20.8 |
| Week 20 | 16.3 | 31.5 | 29.8 |
| Week 24 | 14.2 | 31.5 | 33.1 |
ACR 70 response was defined as \>= 70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 2 | 0 | 0 | 0 |
| Week 4 | 0.8 | 0.4 | 0.8 |
| Week 8 | 0.8 | 3.6 | 2.0 |
| Week 12 | 0.4 | 8.1 | 4.9 |
| Week 16 | 0.8 | 13.7 | 8.2 |
| Week 20 | 3.3 | 15.3 | 13.9 |
| Week 24 | 4.1 | 18.5 | 13.1 |
ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment (PtGA) of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment (PGA) of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (milligram/deciliter \[mg/dL\]).
| percent change | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 2: Swollen Joint Count | -18.9 ± 32.16 | -18.8 ± 39.68 | -18.5 ± 38.38 |
| Week 4: Swollen Joint Count | -27.1 ± 37.29 | -30.5 ± 36.92 | -33.6 ± 37.57 |
| Week 8: Swollen Joint Count | -37.4 ± 39.03 | -46.8 ± 40.68 | -46.7 ± 37.69 |
| Week 12: Swollen Joint Count | -46.1 ± 41.20 | -57.6 ± 39.22 | -58.3 ± 35.42 |
| Week 16: Swollen Joint Count | -48.6 ± 43.01 | -64.1 ± 35.46 | -63.7 ± 34.42 |
| Week 20: Swollen Joint Count | -54.2 ± 41.70 | -69.3 ± 33.63 | -71.4 ± 30.42 |
| Week 24: Swollen Joint Count | -53.9 ± 45.54 | -71.3 ± 34.06 | -73.1 ± 30.67 |
| Week 2: Tender Joint Count | -9.4 ± 25.99 | -10.4 ± 40.31 | -14.8 ± 28.31 |
| Week 4: Tender Joint Count | -14.1 ± 36.04 | -15.0 ± 41.57 | -22.6 ± 32.91 |
| Week 8: Tender Joint Count | -21.9 ± 37.83 | -31.0 ± 42.36 | -33.8 ± 37.58 |
| Week 12: Tender Joint Count | -30.4 ± 37.57 | -40.9 ± 42.73 | -43.0 ± 35.90 |
| Week 16: Tender Joint Count | -30.6 ± 41.87 | -47.0 ± 40.96 | -48.1 ± 37.01 |
| Week 20: Tender Joint Count | -33.9 ± 44.22 | -53.9 ± 37.83 | -54.2 ± 35.43 |
| Week 24: Tender Joint Count | -33.3 ± 44.87 | -54.2 ± 37.15 | -57.3 ± 34.98 |
| Week 2: Patient's Assessment of Pain | 0.05 ± 35.794 | -8.92 ± 32.374 | -4.66 ± 32.229 |
| Week 4: Patient's Assessment of Pain | -0.64 ± 35.849 | -12.58 ± 33.065 | -7.96 ± 37.958 |
| Week 8: Patient's Assessment of Pain | -6.76 ± 34.213 | -21.61 ± 36.705 | -17.05 ± 44.783 |
| Week 12: Patient's Assessment of Pain | -9.01 ± 36.061 | -26.26 ± 40.223 | -25.91 ± 37.862 |
| Week 16: Patient's Assessment of Pain(0-10cm) | -9.70 ± 41.673 | -31.94 ± 42.882 | -27.85 ± 38.913 |
| Week 20: Patient's Assessment of Pain | -10.85 ± 46.497 | -35.16 ± 39.471 | -35.35 ± 39.016 |
| Week 24: Patient's Assessment of Pain | -11.84 ± 48.324 | -38.06 ± 40.565 | -36.52 ± 38.423 |
| Week 2: PtGA of Disease Activity | -1.12 ± 35.882 | -10.15 ± 31.060 | -5.25 ± 32.658 |
| Week 4: PtGA of Disease Activity | -2.27 ± 34.291 | -12.71 ± 34.440 | -11.02 ± 33.605 |
| Week 8: PtGA of Disease Activity | -6.51 ± 35.908 | -21.58 ± 33.697 | -19.13 ± 40.545 |
| Week 12: PtGA of Disease Activity | -9.30 ± 37.185 | -27.86 ± 38.900 | -28.33 ± 34.058 |
| Week 16: PtGA of Disease Activity | -12.34 ± 39.207 | -32.25 ± 40.056 | -28.60 ± 39.759 |
| Week 20: PtGA of Disease Activity | -12.52 ± 42.498 | -35.31 ± 36.205 | -35.11 ± 37.791 |
| Week 24: PtGA of Disease Activity | -13.87 ± 45.650 | -37.05 ± 38.372 | -34.13 ± 51.445 |
| Week 2: PGA of Disease Activity | -9.79 ± 25.687 | -15.06 ± 27.150 | -13.85 ± 23.307 |
| Week 4: PGA of Disease Activity | -16.63 ± 27.573 | -23.72 ± 27.658 | -22.32 ± 28.183 |
| Week 8: PGA of Disease Activity | -23.29 ± 28.416 | -36.54 ± 31.224 | -37.99 ± 29.970 |
| Week 12: PGA of Disease Activity | -27.63 ± 32.379 | -46.54 ± 30.489 | -42.84 ± 31.305 |
| Week 16: PGA of Disease Activity | -31.11 ± 32.023 | -52.02 ± 31.915 | -49.18 ± 31.383 |
| Week 20: PGA of Disease Activity | -34.13 ± 36.576 | -54.32 ± 30.941 | -54.59 ± 29.336 |
| Week 24: PGA of Disease Activity | -36.59 ± 33.740 | -57.22 ± 32.480 | -58.70 ± 28.255 |
| Week 2: HAQ-DI Score | -0.3191 ± 36.62364 | -6.3577 ± 50.81980 | -0.2385 ± 57.44896 |
| Week 4: HAQ-DI Score | -2.8744 ± 46.90795 | -9.1272 ± 53.41051 | -5.1209 ± 85.16625 |
| Week 8: HAQ-DI Score | -5.0965 ± 39.89566 | -12.7684 ± 67.23239 | -9.8081 ± 86.78973 |
| Week 12: HAQ-DI Score | -8.0811 ± 46.90093 | -18.0336 ± 66.96524 | -17.7758 ± 67.44643 |
| Week 16: HAQ-DI Score | -7.1776 ± 48.33253 | -19.3627 ± 70.83578 | -26.6732 ± 53.14973 |
| Week 20: HAQ-DI Score | -10.4296 ± 50.87958 | -24.9496 ± 64.86820 | -28.9317 ± 60.67279 |
| Week 24: HAQ-DI Score | -6.7995 ± 54.78602 | -25.2578 ± 63.15450 | -33.8837 ± 51.59441 |
| Week 2: CRP | 86.677 ± 645.0281 | 0.935 ± 91.3783 | 10.664 ± 132.5947 |
| Week 4: CRP | 28.042 ± 208.6385 | -16.885 ± 79.3501 | 1.128 ± 168.9301 |
| Week 8: CRP | 45.451 ± 322.4433 | -11.214 ± 150.1689 | -17.474 ± 112.3803 |
| Week 12: CRP | 47.034 ± 313.9875 | -25.620 ± 97.1384 | -22.277 ± 122.3489 |
| Week 16: CRP | 28.595 ± 237.6660 | -19.874 ± 134.5210 | -26.592 ± 86.8465 |
| Week 20: CRP | 42.282 ± 284.1330 | -13.551 ± 193.3814 | -28.701 ± 83.0912 |
| Week 24: CRP | 19.263 ± 149.5120 | -27.470 ± 109.5239 | -28.125 ± 87.7229 |
HAQ-DI score assess functional status of participant. It is a 20 question instrument that assess the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative changes from baseline indicate improvement of physical function.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 2 | -0.0594 (-0.1023 to -0.0165) | -0.1423 (-0.1850 to -0.0997) | -0.0795 (-0.1226 to -0.0364) |
| Week 4 | -0.0722 (-0.1196 to -0.0247) | -0.1472 (-0.1944 to -0.1000) | -0.1605 (-0.2081 to -0.1128) |
| Week 8 | -0.0942 (-0.1464 to -0.0420) | -0.2294 (-0.2815 to -0.1773) | -0.2336 (-0.2859 to -0.1813) |
| Week 12 | -0.1332 (-0.1875 to -0.0790) | -0.2870 (-0.3411 to -0.2330) | -0.3010 (-0.3554 to -0.2466) |
| Week 16 | -0.1167 (-0.1753 to -0.0582) | -0.3177 (-0.3760 to -0.2595) | -0.3442 (-0.4029 to -0.2855) |
| Week 20 | -0.1565 (-0.2163 to -0.0968) | -0.3536 (-0.4131 to -0.2941) | -0.4019 (-0.4618 to -0.3420) |
| Week 24 | -0.1300 (-0.1912 to -0.0687) | -0.3672 (-0.4282 to -0.3062) | -0.4004 (-0.4617 to -0.3390) |
HAQ-DI score assess functional status of participant. It is a 20 question instrument that assess the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 2 | 19.9 | 30.7 | 23.2 |
| Week 4 | 23.7 | 32.0 | 35.1 |
| Week 8 | 28.0 | 43.4 | 42.5 |
| Week 12 | 31.8 | 47.4 | 46.9 |
| Week 16 | 30.9 | 50.0 | 51.8 |
| Week 20 | 38.6 | 48.7 | 53.1 |
| Week 24 | 31.4 | 50.0 | 56.1 |
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS 28 (CRP) response criteria was defined as follows: Good response: \<=3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder is defined as achieving a good or moderate DAS28 response at a specific visit.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 2 | 21.5 | 23.8 | 24.5 |
| Week 4 | 32.9 | 38.7 | 40.8 |
| Week 8 | 38.6 | 56.9 | 54.7 |
| Week 12 | 51.2 | 67.3 | 65.7 |
| Week 16 | 51.2 | 69.8 | 72.7 |
| Week 20 | 50.4 | 75.0 | 76.3 |
| Week 24 | 52.4 | 75.4 | 80.0 |
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS 28 (CRP) remission was defined as DAS 28 (CRP) value \<2.6 at the analysis visit.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 2 | 0.8 | 2.4 | 2.4 |
| Week 4 | 2.0 | 5.2 | 4.9 |
| Week 8 | 0.8 | 10.5 | 9.0 |
| Week 12 | 6.1 | 14.1 | 11.8 |
| Week 16 | 6.5 | 18.5 | 16.3 |
| Week 20 | 9.8 | 23.0 | 21.2 |
| Week 24 | 8.5 | 24.6 | 23.3 |
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 2 | -0.29 (-0.37 to -0.21) | -0.42 (-0.50 to -0.33) | -0.43 (-0.51 to -0.35) |
| Week 4 | -0.44 (-0.53 to -0.35) | -0.62 (-0.71 to -0.53) | -0.65 (-0.74 to -0.55) |
| Week 8 | -0.59 (-0.71 to -0.48) | -0.99 (-1.11 to -0.88) | -0.98 (-1.09 to -0.86) |
| Week 12 | -0.85 (-0.97 to -0.73) | -1.27 (-1.39 to -1.15) | -1.22 (-1.35 to -1.10) |
| Week 16 | -0.88 (-1.01 to -0.75) | -1.39 (-1.52 to -1.26) | -1.37 (-1.50 to -1.24) |
| Week 20 | -1.00 (-1.13 to -0.87) | -1.52 (-1.65 to -1.38) | -1.56 (-1.70 to -1.43) |
| Week 24 | -0.97 (-1.11 to -0.84) | -1.59 (-1.72 to -1.45) | -1.62 (-1.76 to -1.49) |
The modified PsARC response was defined as improvement in at least 2 of the four criteria: \>=30% decrease in swollen joint count, \>=30% decrease in tender joint count, \>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) on a VAS (0-100 mm, 0=excellent and 100= poor), \>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 2 | 13.0 | 22.2 | 18.0 |
| Week 4 | 27.2 | 32.7 | 29.8 |
| Week 8 | 35.8 | 48.8 | 50.2 |
| Week 12 | 40.7 | 60.9 | 60.8 |
| Week 16 | 44.7 | 66.5 | 66.5 |
| Week 20 | 46.7 | 72.2 | 69.0 |
| Week 24 | 44.7 | 72.6 | 68.6 |
Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 2 | 16.3 | 17.7 | 17.1 |
| Week 4 | 18.0 | 21.5 | 25.3 |
| Week 8 | 24.7 | 31.0 | 27.6 |
| Week 16 | 30.9 | 47.5 | 40.6 |
| Week 24 | 30.3 | 53.8 | 43.5 |
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 2 | 12.1 | 13.5 | 13.2 |
| Week 4 | 18.2 | 19.8 | 20.7 |
| Week 8 | 29.3 | 30.6 | 31.4 |
| Week 16 | 36.4 | 45.0 | 52.1 |
| Week 24 | 38.4 | 56.8 | 63.6 |
Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 2 | -0.33 (-0.53 to -0.12) | -0.37 (-0.59 to -0.16) | -0.49 (-0.70 to -0.29) |
| Week 4 | -0.46 (-0.68 to -0.24) | -0.56 (-0.79 to -0.33) | -0.69 (-0.92 to -0.47) |
| Week 8 | -0.67 (-0.90 to -0.45) | -0.92 (-1.16 to -0.67) | -0.88 (-1.11 to -0.64) |
| Week 16 | -0.94 (-1.18 to -0.71) | -1.37 (-1.62 to -1.12) | -1.42 (-1.66 to -1.18) |
| Week 24 | -1.03 (-1.25 to -0.81) | -1.60 (-1.84 to -1.37) | -1.52 (-1.75 to -1.29) |
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement of dactylitis.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 2 | -0.21 (-1.11 to 0.69) | -1.11 (-1.95 to -0.26) | -0.78 (-1.61 to 0.05) |
| Week 4 | -1.10 (-2.07 to -0.13) | -2.11 (-3.02 to -1.20) | -1.56 (-2.47 to -0.66) |
| Week 8 | -2.17 (-3.19 to -1.16) | -3.17 (-4.12 to -2.22) | -3.11 (-4.05 to -2.17) |
| Week 16 | -3.40 (-4.42 to -2.38) | -4.88 (-5.84 to -3.92) | -4.80 (-5.75 to -3.85) |
| Week 24 | -4.03 (-4.96 to -3.10) | -5.95 (-6.83 to -5.08) | -5.88 (-6.74 to -5.01) |
PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8 | -0.863 (-1.007 to -0.719) | -1.452 (-1.595 to -1.309) | -1.413 (-1.557 to -1.270) |
| Week 16 | -1.158 (-1.327 to -0.988) | -2.110 (-2.278 to -1.942) | -1.994 (-2.164 to -1.825) |
| Week 24 | -1.336 (-1.516 to -1.156) | -2.403 (-2.582 to -2.225) | -2.399 (-2.579 to -2.219) |
GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\*HAQ-DI\]-\[0.234\*SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0-100, higher scores= better quality of life) and SF-MCS (score ranges from 0-100, higher scores= better quality of life). Total score is from 0-10, lower score=better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | -1.029 (-1.212 to -0.847) | -2.326 (-2.507 to -2.145) | -2.214 (-2.397 to -2.032) |
| Week 24 | -1.198 (-1.395 to -1.001) | -2.593 (-2.789 to -2.397) | -2.589 (-2.786 to -2.392) |
Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
| percentage of work time missed | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | -4.553 (-7.199 to -1.906) | -3.451 (-6.199 to -0.703) | -4.717 (-7.449 to -1.985) |
| Week 24 | -3.491 (-6.403 to -0.578) | -3.103 (-6.062 to -0.144) | -3.827 (-6.826 to -0.828) |
Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
| percentage of impairment | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | -10.281 (-13.887 to -6.675) | -16.054 (-19.699 to -12.409) | -15.083 (-18.655 to -11.511) |
| Week 24 | -10.157 (-13.663 to -6.650) | -19.366 (-22.857 to -15.875) | -19.492 (-22.982 to -16.003) |
Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAi-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
| percentage of overall work impairment | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | -11.232 (-14.962 to -7.501) | -15.926 (-19.694 to 12.159) | -15.808 (-19.501 to -12.115) |
| Week 24 | -10.869 (-14.591 to -7.147) | -19.711 (-23.416 to -16.006) | -20.023 (-23.726 to -16.320) |
Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
| percentage of activity impairment | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | -10.569 (-13.262 to -7.877) | -17.107 (-19.787 to -14.428) | -17.029 (-19.727 to -14.331) |
| Week 24 | -10.320 (-13.071 to -7.570) | -21.467 (-24.204 to -18.729) | -20.480 (-23.226 to -17.734) |
The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | -1.18 (-1.43 to -0.93) | -2.39 (-2.64 to -2.14) | -2.57 (-2.82 to -2.31) |
| Week 24 | -1.30 (-1.57 to -1.04) | -2.94 (-3.20 to -2.68) | -3.09 (-3.35 to -2.83) |
DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL, value \<lower limit of quantification \[LLOQ\] is considered equal to half of the value of LLOQ for numerical calculations), patient assessment of pain (0-10cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 2 | -4.6447 (-5.9287 to -3.3607) | -6.7838 (-8.0642 to -5.5034) | -6.3783 (-7.6664 to -5.0902) |
| Week 4 | -7.6695 (-9.2194 to -6.1197) | -9.9687 (-11.5128 to -8.4246) | -10.2484 (-11.8049 to -8.6919) |
| Week 8 | -10.4480 (-12.1877 to -8.7084) | -15.3303 (-17.0682 to -13.5924) | -15.8657 (-17.6038 to -14.1277) |
| Week 12 | -14.2915 (-16.1107 to -12.4724) | -18.9772 (-20.7912 to -17.1632) | -19.9687 (-21.7915 to -18.1459) |
| Week 16 | -14.8556 (-16.8664 to -12.8448) | -21.6939 (-23.6979 to -19.6899) | -21.4722 (-23.4873 to -19.4571) |
| Week 20 | -16.1375 (-18.1165 to -14.1586) | -23.3163 (-25.2890 to -21.3436) | -24.6844 (-26.6691 to -22.6997) |
| Week 24 | -15.8489 (-17.9229 to -13.7750) | -24.0359 (-26.1019 to -21.9699) | -25.1583 (-27.2341 to -23.0824) |
MDA is a measure that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved the PsA MDA at a visit if the participant has fulfilled at least 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI index score \<= 1).
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | 3.3 | 16.9 | 13.1 |
| Week 24 | 6.1 | 25.0 | 18.8 |
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8: Participants with >=20% Improvement | 38.0 | 46.3 | 53.0 |
| Week 16: Participants with >=20% Improvement | 39.1 | 58.2 | 69.9 |
| Week 24: Participants with >=20% Improvement | 42.4 | 59.7 | 68.7 |
| Week 8: Participants with >=50% Improvement | 6.5 | 17.9 | 18.1 |
| Week 16: Participants with >=50% Improvement | 17.4 | 37.3 | 26.5 |
| Week 24: Participants with >=50% Improvement | 21.7 | 38.8 | 37.3 |
| Week 8: Participants with >=70% Improvement | 3.3 | 11.9 | 4.8 |
| Week 16: Participants with >=70% Improvement | 5.4 | 23.9 | 9.6 |
| Week 24: Participants with >=70% Improvement | 8.7 | 20.9 | 15.7 |
| Week 8: Participants with >=90% Improvement | 0 | 1.5 | 0 |
| Week 16: Participants with >=90% Improvement | 1.1 | 0 | 2.4 |
| Week 24: Participants with >=90% Improvement | 2.2 | 1.5 | 3.6 |
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 75 response: \>=75% improvement in PASI score from baseline.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | 18.6 | 73.3 | 73.9 |
| Week 24 | 23.0 | 79.0 | 78.3 |
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 90 response: \>=90% improvement in PASI score from baseline.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | 8.2 | 55.1 | 53.8 |
| Week 24 | 9.8 | 68.8 | 60.9 |
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 100 response: 100% improvement in PASI score from baseline.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | 3.8 | 27.3 | 33.2 |
| Week 24 | 2.7 | 45.5 | 44.6 |
A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>=2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | 6.0 | 38.6 | 40.8 |
| Week 24 | 7.7 | 50.0 | 51.5 |
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative change from baseline indicates improvement of psoriasis.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | -3.482 (-4.346 to -2.618) | -11.151 (-12.028 to -10.274) | -11.278 (-12.153 to -10.404) |
| Week 24 | -3.904 (-4.748 to -3.059) | -11.407 (-12.265 to -10.549) | -11.471 (-12.325 to -10.617) |
Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. A DLQI score of 0 or 1 indicates psoriasis had no effect at all on patient's life.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8 | 7.6 | 33.5 | 26.6 |
| Week 16 | 10.0 | 51.3 | 45.1 |
| Week 24 | 11.8 | 63.9 | 59.0 |
Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. An improvement of 5 points was considered clinically meaningful.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8 | 30.1 | 71.2 | 69.7 |
| Week 16 | 36.4 | 79.5 | 79.6 |
| Week 24 | 37.8 | 83.3 | 86.8 |
Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. Negative changes from baseline indicate improvement of life quality impacted by psoriasis.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8 | -1.653 (-2.373 to -0.933) | -6.818 (-7.549 to -6.086) | -6.396 (-7.121 to -5.671) |
| Week 16 | -2.410 (-3.109 to -1.710) | -8.545 (-9.255 to -7.835) | -8.147 (-8.853 to -7.441) |
| Week 24 | -2.129 (-2.854 to -1.404) | -8.954 (-9.691 to -8.218) | -8.853 (-9.581 to -8.124) |
In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in swollen joint count (SJC) (66 joints) + tender joint count (TJC) (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | 10.4 | 48.9 | 48.4 |
| Week 24 | 11.5 | 56.8 | 57.1 |
In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | 13.1 | 56.8 | 54.3 |
| Week 24 | 15.3 | 65.3 | 60.9 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change From Baseline in Modified vdH-S Erosion Score at Week 24 | 0.58 (0.33 to 0.83) | 0.36 (0.11 to 0.61) | 0.13 (-0.12 to 0.38) |
The modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). The JSN score is the total JSN score in 40 joints of the two hands and 12 joints of the 2 feet. Each joint is scored from 0 to 4 with 0 indicating no JSN, and 4 indicating a complete loss of joint space, bony ankylosis, or complete luxation, for a maximum JSN score of 208. Higher score indicates more severe joint space narrowing. A positive change from baseline in the modified vdH-S JSN score indicates progression of joint space narrowing.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change From Baseline in Modified vdH-S Joint Space Narrowing (JSN) Score at Week 24 | 0.37 (0.23 to 0.51) | 0.16 (0.02 to 0.30) | 0.16 (0.02 to 0.30) |
Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand (Hand erosion score) scored according to 0 (no erosion) to 5 (complete collapse of bone) for a maximum hand erosion score of 200, and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum foot erosion score of 120. Higher scores indicate more joint damage. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum Hand JSN score of 160 and maximum Foot JSN score of 48. Higher scores indicate more joint damage. Hand Score (sum of Hand Erosion Score and Hand JSN Score) scored as 0-360 and Foot score (sum of foot erosion score and foot JSN score) scored as 0-168. Higher scores indicate more joint damage.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Hand Erosion Score | 0.40 ± 1.555 | 0.18 ± 1.280 | -0.03 ± 1.514 |
| Hand JSN Score | 0.26 ± 1.106 | 0.10 ± 0.637 | 0.08 ± 0.607 |
| Hand Score | 0.66 ± 2.441 | 0.28 ± 1.649 | 0.05 ± 1.881 |
| Foot Erosion Score | 0.14 ± 0.801 | 0.15 ± 0.982 | 0.14 ± 0.894 |
| Foot JSN Score | 0.10 ± 0.516 | 0.02 ± 0.516 | 0.07 ± 0.632 |
| Foot Score | 0.24 ± 1.116 | 0.17 ± 1.180 | 0.21 ± 1.210 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change of <=0 from Baseline | 64.7 | 63.5 | 67.3 |
| Change of <=0.5 from Baseline | 72.1 | 74.4 | 78.0 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change of <=0 from Baseline | 66.8 | 66.3 | 71.4 |
| Change of <=0.5 from Baseline | 72.9 | 76.8 | 80.2 |
The modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). The JSN score is the sum of JSN score in 40 joints of the two hands and 12 joints of the 2 feet. Each joint is scored from 0 - 4 with 0 indicating no JSN, and 4 indicating a complete loss of joint space, bony ankylosis, or complete luxation, for a maximum JSN score of 208. Higher score indicates more severe joint space narrowing. Change from baseline in the modified vdH-S JSN score \<=0 (assessed by both readers) or \<=0.5 (assessed by at least one reader) was considered as no progression of JSN.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change of <=0 from Baseline | 78.6 | 78.8 | 80.1 |
| Change of <=0.5 from Baseline | 85.5 | 88.1 | 88.3 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic progression was defined as change from baseline in the modified vdH-S score \<=SDC of 2.18.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Without Radiographic Progression (Based on the Smallest Detectable Change [SDC]) From Baseline at Week 24 | 86.4 | 87.8 | 89.3 |
Modified vdH-S score is sum of erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC defined as the cut-off above which changes can be detected beyond measurement error. Without radiographic joint erosion progression was defined as change from baseline in modified vdH-S erosion score \<=SDC of 1.83.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Without Radiographic Joint Erosion Progression (Based on SDC) From Baseline at Week 24 | 84.0 | 89.0 | 89.9 |
The modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). The JSN score is the sum of JSN score in 40 joints of the two hands and 12 joints of the 2 feet. Each joint is scored from 0 - 4 with 0 indicating no JSN, and 4 indicating a complete loss of joint space, bony ankylosis, or complete luxation, for a maximum JSN score of 208. Higher score indicates more severe joint space narrowing. The smallest detectable change (SDC) was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic JSN progression was defined as change from baseline in the modified vdH-S JSN score \<=SDC of 1.11.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Without Radiographic JSN Progression (Based on the SDC) From Baseline at Week 24 | 91.3 | 93.5 | 91.7 |
Pencil in Cup or Gross Osteolytis Deformities are radiographic features specific for psoriatic arthritis.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Baseline | 4.5 | 3.6 | 3.7 |
| Week 24 | 4.9 | 3.6 | 3.8 |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8 | 2.75 (1.98 to 3.52) | 4.83 (4.06 to 5.59) | 4.34 (3.56 to 5.1) |
| Week 16 | 3.03 (2.18 to 3.88) | 6.65 (5.80 to 7.49) | 5.93 (5.07 to 6.78) |
| Week 24 | 3.42 (2.53 to 4.32) | 7.39 (6.50 to 8.29) | 7.04 (6.14 to 7.94) |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8 | 1.11 (0.12 to 2.09) | 2.28 (1.30 to 3.27) | 2.87 (1.89 to 3.86) |
| Week 16 | 1.96 (0.91 to 3.01) | 4.28 (3.24 to 5.33) | 3.41 (2.36 to 4.47) |
| Week 24 | 2.14 (1.07 to 3.22) | 4.17 (3.10 to 5.23) | 4.22 (3.14 to 5.29) |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8: Physical Function Score | 2.095 (1.251 to 2.940) | 3.879 (3.038 to 4.720) | 3.936 (3.090 to 4.782) |
| Week 16: Physical Function Score | 2.581 (1.669 to 3.492) | 6.124 (5.218 to 7.030) | 5.618 (4.704 to 6.532) |
| Week 24: Physical Function Score | 3.254 (2.310 to 4.197) | 6.703 (5.764 to 7.642) | 6.624 (5.680 to 7.567) |
| Week 8: Role-physical Score | 2.619 (1.828 to 3.410) | 3.599 (2.812 to 4.387) | 3.107 (2.315 to 3.899) |
| Week 16: Role-physical Score | 2.965 (2.120 to 3.810) | 5.616 (4.776 to 6.455) | 4.942 (4.095 to 5.789) |
| Week 24: Role-physical Score | 3.365 (2.477 to 4.253) | 6.549 (5.666 to 7.433) | 6.241 (5.354 to 7.129) |
| Week 8: Bodily Pain Score | 2.760 (1.974 to 3.546) | 5.456 (4.674 to 6.239) | 4.901 (4.115 to 5.688) |
| Week 16: Bodily Pain Score | 3.086 (2.196 to 3.977) | 7.485 (6.601 to 8.369) | 6.613 (5.721 to 7.505) |
| Week 24: Bodily Pain Score | 3.482 (2.556 to 4.408) | 7.811 (6.890 to 8.733) | 7.739 (6.813 to 8.664) |
| Week 8: General Health Score | 1.662 (0.906 to 2.418) | 4.111 (3.358 to 4.863) | 4.174 (3.418 to 4.931) |
| Week 16: General Health Score | 2.520 (1.681 to 3.358) | 5.719 (4.886 to 6.552) | 4.808 (3.967 to 5.648) |
| Week 24: General Health Score | 2.290 (1.415 to 3.165) | 5.794 (4.924 to 6.665) | 5.269 (4.394 to 6.144) |
| Week 8: Vitality Score | 2.505 (1.574 to 3.436) | 4.286 (3.358 to 5.213) | 4.669 (3.736 to 5.601) |
| Week 16: Vitality Score | 3.554 (2.559 to 4.548) | 6.967 (5.980 to 7.955) | 5.901 (4.904 to 6.898) |
| Week 24: Vitality Score | 3.835 (2.755 to 4.914) | 7.373 (6.299 to 8.447) | 7.009 (5.929 to 8.088) |
| Week 8: Social Function Score | 1.929 (0.976 to 2.882) | 3.337 (2.387 to 4.286) | 4.306 (3.352 to 5.260) |
| Week 16: Social Function Score | 2.884 (1.853 to 3.915) | 5.584 (4.560 to 6.609) | 5.022 (3.989 to 6.055) |
| Week 24: Social Function Score | 2.978 (1.964 to 3.992) | 5.806 (4.796 to 6.816) | 5.922 (4.909 to 6.936) |
| Week 8: Role-emotional Score | 1.108 (0.095 to 2.121) | 2.459 (1.451 to 3.468) | 2.294 (1.280 to 3.307) |
| Week 16: Role-emotional Score | 1.530 (0.499 to 2.562) | 4.497 (3.472 to 5.522) | 3.596 (2.563 to 4.630) |
| Week 24: Role-emotional Score | 1.813 (0.793 to 2.834) | 4.382 (3.367 to 5.398) | 4.255 (3.235 to 5.275) |
| Week 8: Mental Health Score | 1.081 (0.137 to 2.025) | 2.380 (1.440 to 3.320) | 3.048 (2.104 to 3.992) |
| Week 16: Mental Health Score | 2.195 (1.204 to 3.185) | 4.529 (3.546 to 5.513) | 3.896 (2.905 to 4.888) |
| Week 24: Mental Health Score | 2.335 (1.314 to 3.356) | 4.490 (3.474 to 5.506) | 4.767 (3.747 to 5.788) |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8 | 26.4 | 33.1 | 27.3 |
| Week 16 | 31.7 | 42.3 | 31.8 |
| Week 24 | 30.9 | 37.5 | 34.3 |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8 | 37.8 | 45.2 | 41.2 |
| Week 16 | 35.8 | 59.3 | 51.0 |
| Week 24 | 40.2 | 60.1 | 55.9 |
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8 | 2.451 (1.508 to 3.395) | 5.031 (4.092 to 5.970) | 4.850 (3.905 to 5.795) |
| Week 16 | 3.696 (2.675 to 4.717) | 6.977 (5.963 to 7.992) | 6.598 (5.574 to 7.622) |
| Week 24 | 3.559 (2.500 to 4.619) | 7.550 (6.496 to 8.603) | 7.111 (6.051 to 8.171) |
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8 | 45.9 | 56.0 | 51.8 |
| Week 16 | 50.4 | 60.9 | 56.7 |
| Week 24 | 45.5 | 60.5 | 59.6 |
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a vertical line VAS with scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). A higher score indicates better health and positive changes from baseline indicate improvement of health status
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | 6.477 (4.013 to 8.941) | 17.496 (15.049 to 19.943) | 14.646 (12.179 to 17.112) |
| Week 24 | 6.796 (4.298 to 9.294) | 18.371 (15.890 to 20.852) | 18.089 (15.596 to 20.581) |
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a weighted summary index (EQ-5D index), which ranges from 0 (dead) to 1.00 (full health). A higher score indicates better health and positive changes from baseline indicate improvement of health.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | 0.058 (0.043 to 0.074) | 0.112 (0.097 to 0.127) | 0.101 (0.086 to 0.116) |
| Week 24 | 0.053 (0.037 to 0.069) | 0.115 (0.099 to 0.131) | 0.116 (0.100 to 0.132) |
ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 34.0 | 66.8 | 66.2 |
| Week 28 | 48.3 | 71.2 | 72.0 |
| Week 36 | 68.8 | 77.7 | 78.7 |
| Week 44 | 69.7 | 79.7 | 76.7 |
| Week 52 | 68.7 | 79.1 | 75.9 |
ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 15.2 | 32.8 | 34.3 |
| Week 28 | 22.7 | 41.4 | 40.5 |
| Week 36 | 39.3 | 44.1 | 45.7 |
| Week 44 | 43.8 | 48.3 | 48.7 |
| Week 52 | 43.7 | 51.3 | 49.1 |
ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 4.6 | 19.3 | 13.7 |
| Week 28 | 7.6 | 21.1 | 21.1 |
| Week 36 | 15.4 | 27.3 | 24.7 |
| Week 44 | 20.9 | 29.9 | 24.4 |
| Week 52 | 19.2 | 29.5 | 28.1 |
ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24: Swollen Joint Count | 5.8 ± 6.99 | 3.4 ± 5.19 | 4.1 ± 5.77 |
| Week 28: Swollen Joint Count | 4.1 ± 5.17 | 2.9 ± 4.95 | 3.2 ± 5.53 |
| Week 36: Swollen Joint Count | 2.5 ± 3.77 | 2.4 ± 4.58 | 2.7 ± 4.67 |
| Week 44: Swollen Joint Count | 2.1 ± 3.19 | 2.3 ± 4.42 | 2.8 ± 5.65 |
| Week 52: Swollen Joint Count | 2.1 ± 3.59 | 2.1 ± 4.16 | 2.5 ± 4.83 |
| Week 24: Tender Joint Count | 14.4 ± 13.16 | 9.1 ± 9.94 | 10.5 ± 11.82 |
| Week 28: Tender Joint Count | 11.7 ± 11.87 | 7.9 ± 9.02 | 8.6 ± 10.03 |
| Week 36: Tender Joint Count | 8.5 ± 10.00 | 7.0 ± 8.72 | 7.5 ± 9.25 |
| Week 44: Tender Joint Count | 7.5 ± 9.42 | 6.3 ± 8.45 | 7.0 ± 9.42 |
| Week 52: Tender Joint Count | 7.4 ± 10.24 | 6.2 ± 8.18 | 7.3 ± 9.46 |
| Week 24: Patient's Assessment of Pain | 5.21 ± 2.368 | 3.77 ± 2.457 | 3.70 ± 2.193 |
| Week 28: Patient's Assessment of Pain | 4.66 ± 2.341 | 3.50 ± 2.311 | 3.45 ± 2.259 |
| Week 36: Patient's Assessment of Pain | 3.78 ± 2.297 | 3.28 ± 2.336 | 3.20 ± 2.242 |
| Week 44: Patient's Assessment of Pain | 3.67 ± 2.312 | 3.22 ± 2.370 | 3.24 ± 2.277 |
| Week 52: Patient's Assessment of Pain | 3.53 ± 2.253 | 3.10 ± 2.333 | 3.21 ± 2.371 |
| Week 24: PtGA of Disease Activity | 5.29 ± 2.367 | 4.01 ± 2.516 | 3.93 ± 2.276 |
| Week 28: PtGA of Disease Activity | 4.75 ± 2.338 | 3.76 ± 2.348 | 3.62 ± 2.275 |
| Week 36: PtGA of Disease Activity | 3.84 ± 2.295 | 3.52 ± 2.390 | 3.30 ± 2.318 |
| Week 44: PtGA of Disease Activity | 3.78 ± 2.378 | 3.36 ± 2.447 | 3.50 ± 2.323 |
| Week 52: PtGA of Disease Activity | 3.68 ± 2.318 | 3.23 ± 2.383 | 3.28 ± 2.354 |
| Week 24: PGA of Disease Activity | 4.22 ± 2.342 | 2.74 ± 2.113 | 2.66 ± 1.906 |
| Week 28: PGA of Disease Activity | 3.27 ± 1.930 | 2.44 ± 1.941 | 2.33 ± 1.668 |
| Week 36: PGA of Disease Activity | 2.28 ± 1.594 | 2.10 ± 1.777 | 2.06 ± 1.716 |
| Week 44: PGA of Disease Activity | 2.06 ± 1.649 | 1.97 ± 1.842 | 1.93 ± 1.631 |
| Week 52: PGA of Disease Activity | 1.90 ± 1.654 | 1.77 ± 1.645 | 1.77 ± 1.616 |
| Week 24: HAQ-DI score | 1.1350 ± 0.61984 | 0.8766 ± 0.59893 | 0.8194 ± 0.57287 |
| Week 28: HAQ-DI score | 1.0457 ± 0.59051 | 0.8497 ± 0.61863 | 0.7985 ± 0.56677 |
| Week 36: HAQ-DI score | 0.9621 ± 0.60695 | 0.8091 ± 0.61588 | 0.7376 ± 0.56257 |
| Week 44: HAQ-DI score | 0.9117 ± 0.63353 | 0.7927 ± 0.59979 | 0.7804 ± 0.57721 |
| Week 52: HAQ-DI score | 0.9069 ± 0.63695 | 0.7917 ± 0.59527 | 0.7364 ± 0.58655 |
| Week 24: CRP | 1.543 ± 2.1572 | 0.961 ± 1.2868 | 0.790 ± 0.8390 |
| Week 28: CRP | 1.120 ± 1.5140 | 0.956 ± 1.3749 | 0.885 ± 1.0299 |
| Week 36: CRP | 0.920 ± 1.4674 | 0.892 ± 1.3109 | 0.837 ± 1.0730 |
| Week 44: CRP | 0.858 ± 1.0558 | 0.812 ± 1.0139 | 0.992 ± 1.9875 |
| Week 52: CRP | 0.907 ± 1.5985 | 0.937 ± 1.2422 | 0.910 ± 1.2756 |
ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24: Swollen Joint Count | -6.4 ± 7.25 | -8.2 ± 6.09 | -8.8 ± 5.50 |
| Week 28: Swollen Joint Count | -8.1 ± 6.99 | -8.8 ± 5.98 | -9.6 ± 6.65 |
| Week 36: Swollen Joint Count | -9.9 ± 6.47 | -9.2 ± 5.81 | -10.2 ± 6.76 |
| Week 44: Swollen Joint Count | -10.1 ± 6.77 | -9.3 ± 6.24 | -10.2 ± 6.28 |
| Week 52: Swollen Joint Count | -10.2 ± 6.79 | -9.6 ± 6.28 | -10.4 ± 6.17 |
| Week 24: Tender Joint Count | -7.0 ± 10.91 | -10.4 ± 9.51 | -11.9 ± 9.98 |
| Week 28: Tender Joint Count | -9.7 ± 10.78 | -11.7 ± 9.24 | -13.7 ± 10.53 |
| Week 36: Tender Joint Count | -13.2 ± 10.78 | -12.5 ± 9.68 | -14.6 ± 10.31 |
| Week 44: Tender Joint Count | -14.0 ± 11.02 | -13.3 ± 9.56 | -15.2 ± 10.25 |
| Week 52: Tender Joint Count | -14.1 ± 11.39 | -13.4 ± 10.03 | -15.0 ± 10.51 |
| Week 24: Patient's Assessment of Pain | -1.08 ± 2.441 | -2.55 ± 2.477 | -2.41 ± 2.335 |
| Week 28: Patient's Assessment of Pain | -1.63 ± 2.420 | -2.83 ± 2.519 | -2.66 ± 2.416 |
| Week 36: Patient's Assessment of Pain | -2.51 ± 2.588 | -3.02 ± 2.534 | -2.89 ± 2.540 |
| Week 44: Patient's Assessment of Pain | -2.62 ± 2.640 | -3.07 ± 2.644 | -2.87 ± 2.601 |
| Week 52: Patient's Assessment of Pain | -2.75 ± 2.659 | -3.20 ± 2.555 | -2.89 ± 2.681 |
| Week 24: PtGA of Disease Activity | -1.25 ± 2.601 | -2.52 ± 2.490 | -2.40 ± 2.383 |
| Week 28: PtGA of Disease Activity | -1.79 ± 2.543 | -2.79 ± 2.560 | -2.70 ± 2.382 |
| Week 36: PtGA of Disease Activity | -2.70 ± 2.555 | -2.99 ± 2.569 | -3.01 ± 2.445 |
| Week 44: PtGA of Disease Activity | -2.76 ± 2.741 | -3.15 ± 2.650 | -2.86 ± 2.559 |
| Week 52: PtGA of Disease Activity | -2.85 ± 2.757 | -3.29 ± 2.558 | -3.06 ± 2.527 |
| Week 24: PGA of Disease Activity | -2.45 ± 2.248 | -3.84 ± 2.316 | -3.93 ± 2.227 |
| Week 28: PGA of Disease Activity | -3.42 ± 2.189 | -4.16 ± 2.175 | -4.28 ± 2.054 |
| Week 36: PGA of Disease Activity | -4.39 ± 2.052 | -4.49 ± 2.116 | -4.53 ± 2.173 |
| Week 44: PGA of Disease Activity | -4.61 ± 2.043 | -4.55 ± 2.139 | -4.70 ± 2.084 |
| Week 52: PGA of Disease Activity | -4.77 ± 2.007 | -4.78 ± 1.996 | -4.81 ± 2.120 |
| Week 24: HAQ-DI score | -0.1646 ± 0.53253 | -0.4044 ± 0.54194 | -0.4257 ± 0.50337 |
| Week 28: HAQ-DI score | -0.2547 ± 0.50426 | -0.4383 ± 0.55648 | -0.4429 ± 0.51556 |
| Week 36: HAQ-DI score | -0.3423 ± 0.52951 | -0.4702 ± 0.55698 | -0.5000 ± 0.55438 |
| Week 44: HAQ-DI score | -0.3868 ± 0.57065 | -0.4824 ± 0.57091 | -0.4652 ± 0.56121 |
| Week 52: HAQ-DI score | -0.3848 ± 0.58049 | -0.4824 ± 0.56167 | -0.5082 ± 0.58255 |
| Week 24: CRP | -0.547 ± 2.5657 | -1.038 ± 2.0932 | -1.052 ± 2.1295 |
| Week 28: CRP | -0.993 ± 2.3669 | -1.028 ± 2.0476 | -0.976 ± 2.1663 |
| Week 36: CRP | -1.202 ± 2.3234 | -1.098 ± 2.1102 | -1.020 ± 2.1985 |
| Week 44: CRP | -1.262 ± 2.5377 | -1.145 ± 2.1378 | -0.861 ± 2.8133 |
| Week 52: CRP | -1.237 ± 2.8242 | -1.021 ± 2.2289 | -0.937 ± 2.4116 |
ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).
| percent change | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24: Swollen Joint Count | -53.44 ± 45.655 | -72.06 ± 33.971 | -73.17 ± 30.614 |
| Week 28: Swollen Joint Count | -66.15 ± 37.305 | -78.02 ± 30.197 | -78.85 ± 28.109 |
| Week 36: Swollen Joint Count | -80.38 ± 28.144 | -82.82 ± 26.054 | -81.49 ± 27.338 |
| Week 44: Swollen Joint Count | -81.85 ± 26.328 | -82.10 ± 27.742 | -83.32 ± 24.289 |
| Week 52: Swollen Joint Count | -82.34 ± 30.494 | -83.18 ± 30.121 | -84.07 ± 24.070 |
| Week 24: Tender Joint Count | -32.53 ± 44.850 | -54.81 ± 37.134 | -57.11 ± 35.073 |
| Week 28: Tender Joint Count | -45.52 ± 41.132 | -62.48 ± 32.820 | -64.31 ± 31.767 |
| Week 36: Tender Joint Count | -62.21 ± 34.292 | -66.12 ± 32.829 | -68.50 ± 30.000 |
| Week 44: Tender Joint Count | -65.88 ± 33.344 | -70.90 ± 29.688 | -72.10 ± 27.670 |
| Week 52: Tender Joint Count | -67.29 ± 35.583 | -70.29 ± 31.985 | -69.82 ± 32.122 |
| Week 24: Patient's Assessment of Pain | -11.52 ± 48.647 | -38.44 ± 40.734 | -36.64 ± 38.086 |
| Week 28: Patient's Assessment of Pain | -22.20 ± 42.404 | -42.17 ± 41.660 | -41.02 ± 39.624 |
| Week 36: Patient's Assessment of Pain | -35.65 ± 43.207 | -45.89 ± 40.125 | -43.29 ± 44.442 |
| Week 44: Patient's Assessment of Pain | -37.45 ± 43.534 | -46.48 ± 41.725 | -43.60 ± 42.560 |
| Week 52: Patient's Assessment of Pain | -38.23 ± 47.430 | -49.00 ± 39.082 | -43.51 ± 45.742 |
| Week 24: PtGA of Disease Activity | -13.78 ± 45.943 | -37.18 ± 38.628 | -33.90 ± 51.672 |
| Week 28: PtGA of Disease Activity | -23.78 ± 40.895 | -39.92 ± 40.228 | -40.70 ± 36.587 |
| Week 36: PtGA of Disease Activity | -38.82 ± 37.114 | -44.21 ± 36.982 | -45.52 ± 38.659 |
| Week 44: PtGA of Disease Activity | -38.45 ± 43.993 | -46.64 ± 38.228 | -42.45 ± 39.243 |
| Week 52: PtGA of Disease Activity | -39.34 ± 44.933 | -48.73 ± 38.925 | -45.50 ± 40.653 |
| Week 24: PGA of Disease Activity | -36.13 ± 33.383 | -57.60 ± 32.634 | -59.06 ± 28.137 |
| Week 28: PGA of Disease Activity | -49.72 ± 30.129 | -62.89 ± 28.027 | -64.14 ± 25.784 |
| Week 36: PGA of Disease Activity | -64.57 ± 25.695 | -67.98 ± 25.989 | -67.74 ± 28.029 |
| Week 44: PGA of Disease Activity | -68.32 ± 25.560 | -69.79 ± 26.949 | -70.27 ± 24.516 |
| Week 52: PGA of Disease Activity | -71.05 ± 25.056 | -73.09 ± 24.133 | -72.46 ± 24.485 |
| Week 24: HAQ-DI score | -6.86 ± 54.753 | -25.47 ± 63.639 | -33.72 ± 51.766 |
| Week 28: HAQ-DI score | -15.66 ± 49.522 | -28.82 ± 73.930 | -33.91 ± 59.310 |
| Week 36: HAQ-DI score | -23.34 ± 46.393 | -31.95 ± 78.348 | -37.74 ± 56.329 |
| Week 44: HAQ-DI score | -27.01 ± 49.683 | -33.84 ± 60.164 | -32.45 ± 72.337 |
| Week 52: HAQ-DI score | -26.83 ± 54.380 | -33.49 ± 63.823 | -35.02 ± 65.765 |
| Week 24: CRP | 19.81 ± 150.274 | -26.90 ± 110.466 | -28.35 ± 88.038 |
| Week 28: CRP | -0.80 ± 155.637 | -21.09 ± 144.287 | 15.69 ± 468.613 |
| Week 36: CRP | -6.70 ± 183.299 | -25.47 ± 157.839 | -23.97 ± 104.641 |
| Week 44: CRP | -8.33 ± 143.843 | -37.54 ± 76.302 | -17.44 ± 127.594 |
| Week 52: CRP | -0.25 ± 208.267 | -23.15 ± 104.461 | -0.99 ± 193.429 |
ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
| percentage of participants | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|
| Percentage of Participants Who Maintained an ACR 20 Response at Week 52 Among Participants Who Achieved an ACR 20 Response at Week 24 | 91.7 | 86.8 |
ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
| percentage of participants | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|
| Percentage of Participants Who Maintained an ACR 50 Response at Week 52 Among Participants Who Achieved an ACR 50 Response at Week 24 | 87.2 | 79.2 |
ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 millimeters \[mm\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
| percentage of participants | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|
| Percentage of Participants Who Maintained an ACR 70 Response at Week 52 Among Participants Who Achieved an ACR 70 Response at Week 24 | 82.6 | 75.0 |
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | -0.1646 ± 0.53253 | -0.4044 ± 0.54194 | -0.4257 ± 0.50337 |
| Week 28 | -0.2547 ± 0.50426 | -0.4383 ± 0.55648 | -0.4429 ± 0.51556 |
| Week 36 | -0.3423 ± 0.52951 | -0.4702 ± 0.55698 | -0.5000 ± 0.55438 |
| Week 44 | -0.3868 ± 0.57065 | -0.4824 ± 0.57091 | -0.4652 ± 0.56121 |
| Week 52 | -0.3848 ± 0.58049 | -0.4824 ± 0.56167 | -0.5082 ± 0.58255 |
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 34.1 | 52.5 | 58.3 |
| Week 28 | 42.4 | 58.4 | 63.4 |
| Week 36 | 48.4 | 58.2 | 61.9 |
| Week 44 | 50.9 | 60.0 | 61.4 |
| Week 52 | 50.5 | 60.9 | 62.9 |
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.
| percentage of participants | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|
| Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 52 Among Participants Who Achieved a HAQ-DI Response at Week 24 | 92.0 | 88.6 |
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS28 (CRP) response criteria was defined as follows: Good response: \<=3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder was defined as achieving a good or moderate DAS28 response at a specific visit.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 55.5 | 79.0 | 83.8 |
| Week 28 | 72.3 | 85.0 | 85.9 |
| Week 36 | 86.5 | 86.9 | 92.5 |
| Week 44 | 91.0 | 91.8 | 91.9 |
| Week 52 | 89.0 | 89.7 | 89.4 |
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS28 (CRP) remission was defined as DAS28 (CRP) value \<2.6 at the analysis visit.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 9.3 | 25.6 | 24.4 |
| Week 28 | 13.2 | 27.5 | 30.4 |
| Week 36 | 25.7 | 36.0 | 39.5 |
| Week 44 | 30.0 | 38.4 | 38.0 |
| Week 52 | 34.2 | 39.7 | 39.6 |
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | -1.02 ± 1.101 | -1.63 ± 1.051 | -1.68 ± 0.976 |
| Week 28 | -1.38 ± 1.099 | -1.78 ± 1.038 | -1.86 ± 1.066 |
| Week 36 | -1.92 ± 1.086 | -1.97 ± 1.114 | -2.08 ± 1.088 |
| Week 44 | -2.04 ± 1.098 | -2.09 ± 1.107 | -2.08 ± 1.063 |
| Week 52 | -2.14 ± 1.142 | -2.08 ± 1.121 | -2.11 ± 1.128 |
The modified PsARC response was defined as improvement in at least 2 of the four criteria: \>=30% decrease in swollen joint count, \>=30% decrease in tender joint count, \>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) on a VAS (0-100 mm, 0=excellent and 100= poor), \>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 46.6 | 76.4 | 72.8 |
| Week 28 | 64.6 | 79.3 | 83.1 |
| Week 36 | 78.7 | 82.3 | 84.3 |
| Week 44 | 77.6 | 83.7 | 82.2 |
| Week 52 | 81.2 | 86.3 | 82.9 |
Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 32.6 | 57.6 | 45.5 |
| Week 52 | 67.3 | 65.5 | 60.0 |
Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | -1.1 ± 1.66 | -1.6 ± 1.75 | -1.6 ± 1.63 |
| Week 52 | -2.1 ± 1.61 | -1.9 ± 1.65 | -2.0 ± 1.78 |
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 41.1 | 60.7 | 68.1 |
| Week 52 | 78.5 | 81.9 | 81.1 |
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. A higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement in dactylitis.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | -4.6 ± 7.88 | -6.1 ± 7.83 | -6.6 ± 7.84 |
| Week 52 | -7.4 ± 9.18 | -7.3 ± 9.74 | -7.4 ± 8.59 |
PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | -1.399 ± 1.3169 | -2.496 ± 1.5024 | -2.506 ± 1.2578 |
| Week 52 | -3.041 ± 1.4979 | -3.197 ± 1.5212 | -3.161 ± 1.4646 |
PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 8.1 | 31.6 | 24.6 |
| Week 52 | 38.5 | 45.3 | 46.3 |
GRACE index is a composite PsA disease activity score converted from AMDF, which was derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100= poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL =25.355 + \[2.367\*HAQ-DI\] - \[0.234\*SF-PCS\] - \[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0 to 100, higher scores= better quality of life) and SF-MCS (score ranges from 0 to 100, higher scores= better quality of life). The total score is from 0-10, where lower score indicates better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | -1.260 ± 1.4909 | -2.658 ± 1.6770 | -2.672 ± 1.4589 |
| Week 52 | -3.085 ± 1.6277 | -3.271 ± 1.6453 | -3.267 ± 1.5646 |
GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), PtGA of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), PtGA of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\*HAQ-DI\]-\[0.234\*SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score range= 0-100, higher scores= better quality of life) and SF-MCS (score range=0-100, higher scores= better quality of life). Total score is 0-10, lower score=better response. Higher score= more active disease activity. Negative change from baseline indicates improvement of PsA disease activity. GRACE low disease activity is GRACE score \<=2.3 at the analysis visit.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 7.6 | 29.5 | 27.6 |
| Week 52 | 34.9 | 43.2 | 43.0 |
DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL), patient assessment of pain (0-10cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | -16.377 ± 19.1814 | -24.718 ± 16.7967 | -26.578 ± 15.3393 |
| Week 28 | -22.199 ± 17.9394 | -26.573 ± 15.5254 | -29.613 ± 17.6129 |
| Week 36 | -29.251 ± 18.1137 | -28.889 ± 16.4372 | -31.782 ± 16.7698 |
| Week 44 | -30.754 ± 18.5016 | -30.108 ± 16.6013 | -32.126 ± 15.7605 |
| Week 52 | -31.209 ± 18.9981 | -30.512 ± 17.5074 | -32.282 ± 16.6320 |
The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | -1.34 ± 2.144 | -2.97 ± 2.382 | -3.32 ± 2.098 |
| Week 52 | -3.75 ± 2.391 | -3.84 ± 2.449 | -4.10 ± 2.387 |
The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. mCPDAI low disease activity is defined as mCPDAI score \<=3.2 at the analysis visit.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 15.1 | 48.9 | 43.5 |
| Week 52 | 56.3 | 61.1 | 60.1 |
MDA is a measure that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved the PsA MDA at a visit if the participant has fulfilled at least 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI index score \<= 1).
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 6.3 | 26.5 | 19.7 |
| Week 52 | 31.6 | 32.9 | 36.8 |
A measurement that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved VLDA at a visit if the participant fulfilled all 7 criteria (tender joint count \<=1; swollen joint count \<=1; PASI \<=1; patient pain VAS score of \<=15; patient global disease activity VAS \[arthritis and psoriasis\] score of \<=20; Health Assessment Questionnaire (HAQ) score \<=0.5; and tender entheseal points \<=1) at that visit.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 1.3 | 4.6 | 5.1 |
| Week 52 | 6.9 | 17.1 | 12.2 |
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | -1.374 ± 2.4269 | -2.652 ± 2.3825 | -2.674 ± 1.9941 |
| Week 52 | -2.986 ± 2.4945 | -2.883 ± 2.5193 | -3.084 ± 2.1843 |
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24: Participants with >=20% Improvement | 44.0 | 62.5 | 73.1 |
| Week 52: Participants with >=20% Improvement | 71.6 | 70.3 | 79.7 |
| Week 24: Participants with >=50% Improvement | 22.0 | 40.6 | 39.7 |
| Week 52: Participants with >=50% Improvement | 50.0 | 42.2 | 50.6 |
| Week 24: Participants with >=70% Improvement | 8.8 | 21.9 | 16.7 |
| Week 52: Participants with >=70% Improvement | 23.9 | 26.6 | 30.4 |
| Week 24: Participants with >=90% Improvement | 2.2 | 1.6 | 3.8 |
| Week 52: Participants with >=90% Improvement | 6.8 | 10.9 | 8.9 |
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative change from baseline indicates improvement of psoriasis.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | -2.989 ± 6.1515 | -11.685 ± 12.3496 | -12.574 ± 11.8391 |
| Week 52 | -11.016 ± 9.9801 | -11.977 ± 12.0847 | -12.857 ± 11.3052 |
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 50 response: \>=50% improvement in PASI score from baseline.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 39.8 | 94.8 | 93.8 |
| Week 52 | 95.9 | 97.1 | 98.3 |
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 23.3 | 80.8 | 81.8 |
| Week 52 | 88.4 | 88.8 | 91.9 |
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 90 response: \>=90% improvement in PASI score from baseline.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 10.2 | 70.3 | 63.6 |
| Week 52 | 76.7 | 77.1 | 81.5 |
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 100 response: 100% improvement in PASI score from baseline.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 2.8 | 46.5 | 46.6 |
| Week 52 | 55.2 | 54.7 | 61.3 |
In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in SJC (66 joints)+TJC (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 11.4 | 58.1 | 59.7 |
| Week 52 | 59.6 | 73.5 | 69.9 |
In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 15.3 | 66.9 | 63.6 |
| Week 52 | 70.9 | 79.4 | 76.3 |
A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 19.9 | 72.1 | 71.0 |
| Week 52 | 84.3 | 77.1 | 84.4 |
A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 8.0 | 51.2 | 52.8 |
| Week 52 | 66.9 | 60.0 | 66.5 |
Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. A DLQI score of 0 or 1 indicates psoriasis had no effect at all on patient's life.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 12.1 | 65.6 | 61.4 |
| Week 52 | 56.8 | 68.6 | 68.7 |
Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. An improvement of 5 points was considered clinically meaningful.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 40.7 | 85.4 | 90.3 |
| Week 52 | 84.8 | 92.2 | 89.4 |
Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. Negative changes from baseline indicate improvement of life quality impacted by psoriasis.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | -2.142 ± 6.4593 | -8.901 ± 7.3657 | -9.249 ± 7.0988 |
| Week 52 | -8.815 ± 7.2714 | -9.235 ± 7.3840 | -9.839 ± 6.8777 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change From Baseline in Modified vdH-S Score at Week 52 | 1.25 ± 3.508 | 0.97 ± 3.623 | 1.07 ± 3.843 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change in Total Modified vdH-S Score From Week 24 to Week 52 | 0.25 ± 1.635 | 0.23 ± 1.808 | 0.62 ± 2.530 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change From Baseline in Modified vdH-S Erosion Score at Week 52 | 0.92 ± 2.497 | 0.67 ± 2.707 | 0.70 ± 2.631 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change in Modified vdH-S Erosion Score From Week 24 to Week 52 | 0.17 ± 1.277 | 0.10 ± 1.422 | 0.39 ± 1.725 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change From Baseline in Modified vdH-S JSN Score at Week 52 | 0.33 ± 1.356 | 0.29 ± 1.272 | 0.38 ± 1.633 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change in Modified vdH-S JSN Score From Week 24 to Week 52 | 0.07 ± 0.635 | 0.13 ± 0.705 | 0.23 ± 1.088 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand (Hand erosion score) scored according to 0 (no erosion) to 5 (complete collapse of bone) for a maximum hand erosion score of 200, and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum foot erosion score of 120. Higher scores indicate more joint damage. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum Hand JSN score of 160 and maximum Foot JSN score of 48. Higher scores indicate more joint damage. Hand Score (sum of Hand Erosion Score and Hand JSN Score) scored as 0-360 and Foot score (sum of foot erosion score and foot JSN score) scored as 0-168. Higher scores indicate more joint damage.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Hand Erosion Score | 0.66 ± 1.815 | 0.37 ± 1.969 | 0.35 ± 1.830 |
| Hand JSN Score | 0.29 ± 1.181 | 0.19 ± 0.913 | 0.22 ± 1.235 |
| Hand Score | 0.95 ± 2.706 | 0.56 ± 2.589 | 0.57 ± 2.759 |
| Foot Erosion Score | 0.26 ± 1.014 | 0.30 ± 1.339 | 0.34 ± 1.413 |
| Foot JSN Score | 0.04 ± 0.353 | 0.10 ± 0.660 | 0.16 ± 0.864 |
| Foot Score | 0.30 ± 1.220 | 0.40 ± 1.687 | 0.50 ± 1.939 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change of <=0 from Baseline | 57.4 | 55.7 | 56.8 |
| Change of <=0.5 from Baseline | 67.4 | 67.2 | 72.1 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change of <=0 from Baseline | 58.3 | 59.6 | 60.3 |
| Change of <=0.5 from Baseline | 70.4 | 71.1 | 72.1 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change of <=0 from Baseline | 78.7 | 75.3 | 79.5 |
| Change of <=0.5 from Baseline | 88.3 | 86.0 | 86.5 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic progression was defined as change from baseline in the modified vdH-S score \<=SDC of 2.39.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Without Radiographic Progression Based on the (SDC) From Baseline at Week 52 | 80.4 | 82.6 | 85.2 |
Modified vdH-S score is sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic joint erosion progression was defined as change from baseline in modified vdH-S erosion score \<=SDC of 2.22.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Without Radiographic Joint Erosion Progression Based on (SDC) From Baseline at Week 52 | 82.2 | 84.3 | 87.3 |
Modified vdH-S score is sum of erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as cut-off above which changes can be detected beyond measurement error. Without radiographic JSN progression was defined as change from baseline in modified vdH-S JSN score \<=SDC of 1.02.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Without Radiographic JSN Progression Based on (SDC) From Baseline at Week 52 | 91.3 | 91.5 | 90.4 |
Percentage of Participants with Pencil in cup or Gross Osteolysis Deformities were reported. Pencil in Cup or Gross Osteolytis Deformities are radiographic features specific for psoriatic arthritis.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Baseline | 6.9 | 4.6 | 6.9 |
| Week 52 | 7.8 | 5.1 | 7.0 |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 3.782 ± 7.1776 | 7.838 ± 8.0335 | 7.183 ± 6.9793 |
| Week 52 | 8.124 ± 8.2192 | 9.511 ± 8.3176 | 8.960 ± 8.5891 |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 2.211 ± 10.1368 | 4.452 ± 9.9560 | 4.128 ± 9.1814 |
| Week 52 | 4.297 ± 10.8960 | 4.465 ± 9.7780 | 4.076 ± 9.1101 |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24: Physical Function Score | 3.602 ± 7.7388 | 7.052 ± 8.5020 | 6.772 ± 7.5920 |
| Week 52: Physical Function Score | 7.722 ± 8.9480 | 8.489 ± 8.8599 | 8.374 ± 8.7884 |
| Week 24: Role-physical Score | 3.695 ± 7.5950 | 6.897 ± 7.7240 | 6.381 ± 7.2203 |
| Week 52: Role-physical Score | 6.560 ± 8.5399 | 7.677 ± 8.2995 | 7.344 ± 7.7145 |
| Week 24: Bodily Pain Score | 3.882 ± 8.3009 | 8.333 ± 8.3852 | 7.833 ± 7.3390 |
| Week 52: Bodily Pain Score | 8.460 ± 8.4659 | 10.238 ± 8.7185 | 9.457 ± 9.7977 |
| Week 24: General Health Score | 2.255 ± 7.2176 | 5.963 ± 7.8794 | 5.067 ± 7.4182 |
| Week 52: General Health Score | 6.396 ± 8.5589 | 7.173 ± 7.2703 | 6.366 ± 8.4199 |
| Week 24: Vitality Score | 4.224 ± 9.0878 | 7.914 ± 9.4638 | 6.970 ± 9.4889 |
| Week 52: Vitality Score | 7.879 ± 9.4160 | 8.646 ± 9.5131 | 7.654 ± 9.3905 |
| Week 24: Social Function Score | 3.088 ± 10.4330 | 6.551 ± 9.7076 | 5.892 ± 8.5510 |
| Week 52: Social Function Score | 6.278 ± 10.9444 | 7.199 ± 10.1315 | 6.787 ± 9.5326 |
| Week 24: Role-emotional Score | 1.910 ± 10.0772 | 4.535 ± 10.1304 | 4.107 ± 8.9473 |
| Week 52: Role-emotional Score | 4.057 ± 10.8795 | 4.970 ± 10.1685 | 4.607 ± 8.7627 |
| Week 24: Mental Health Score | 2.583 ± 9.2222 | 4.605 ± 9.7905 | 4.752 ± 8.9336 |
| Week 52: Mental Health Score | 5.153 ± 10.0724 | 4.829 ± 9.3665 | 4.741 ± 9.3825 |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 42.2 | 63.4 | 58.5 |
| Week 52 | 63.0 | 67.1 | 65.5 |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 32.5 | 40.3 | 36.8 |
| Week 52 | 41.7 | 44.9 | 38.9 |
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 3.844 ± 9.0440 | 8.034 ± 9.8888 | 6.970 ± 8.6274 |
| Week 52 | 7.548 ± 9.3745 | 8.927 ± 9.4646 | 7.686 ± 9.0833 |
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 49.4 | 63.9 | 62.8 |
| Week 52 | 68.3 | 69.7 | 68.6 |
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a vertical line VAS with scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). A higher score indicates better health and positive changes from baseline indicate improvement of health status.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 8.456 ± 25.7204 | 19.282 ± 23.5220 | 17.500 ± 22.6981 |
| Week 52 | 21.474 ± 25.5974 | 23.295 ± 23.6270 | 19.983 ± 24.7643 |
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a weighted summary index (EQ-5D index), which ranges from 0 (dead) to 1.00 (full health). A higher score indicates better health and positive changes from baseline indicate improvement of health.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 0.060 ± 0.1558 | 0.124 ± 0.1476 | 0.117 ± 0.1307 |
| Week 52 | 0.137 ± 0.1605 | 0.146 ± 0.1587 | 0.135 ± 0.1469 |
Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | -5.64 ± 28.355 | -3.77 ± 28.029 | -1.20 ± 17.127 |
| Week 52 | -5.37 ± 25.365 | -4.47 ± 20.454 | -1.74 ± 17.084 |
Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | -12.14 ± 29.027 | -21.28 ± 25.621 | -20.08 ± 22.084 |
| Week 52 | -21.27 ± 31.502 | -27.93 ± 25.263 | -22.10 ± 26.172 |
Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | -13.42 ± 29.916 | -21.68 ± 27.065 | -20.90 ± 22.814 |
| Week 52 | -22.06 ± 32.092 | -28.19 ± 25.536 | -22.24 ± 26.920 |
Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | -10.80 ± 26.131 | -23.03 ± 25.559 | -21.07 ± 21.493 |
| Week 52 | -24.13 ± 27.436 | -27.14 ± 25.657 | -26.11 ± 25.361 |
ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 68.7 | 78.9 | 77.0 |
| Week 68 | 77.0 | 85.2 | 80.7 |
| Week 76 | 75.6 | 83.1 | 82.5 |
| Week 84 | 80.1 | 85.1 | 80.6 |
| Week 100 | 79.2 | 82.1 | 84.9 |
ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 44.3 | 50.9 | 49.6 |
| Week 68 | 49.5 | 60.8 | 58.6 |
| Week 76 | 50.9 | 56.0 | 58.3 |
| Week 84 | 56.3 | 63.8 | 57.8 |
| Week 100 | 55.2 | 60.7 | 62.3 |
ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 19.5 | 29.7 | 28.3 |
| Week 68 | 27.8 | 35.5 | 36.1 |
| Week 76 | 27.9 | 36.4 | 32.7 |
| Week 84 | 29.6 | 42.8 | 39.4 |
| Week 100 | 34.3 | 39.3 | 38.6 |
ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52: Swollen Joint Count | 2.1 ± 3.58 | 2.1 ± 4.18 | 2.5 ± 4.83 |
| Week 68: Swollen Joint Count | 1.6 ± 3.10 | 1.7 ± 3.87 | 2.0 ± 3.79 |
| Week 76: Swollen Joint Count | 1.6 ± 3.17 | 1.8 ± 3.72 | 2.3 ± 4.59 |
| Week 84: Swollen Joint Count | 1.6 ± 3.02 | 1.6 ± 3.82 | 2.0 ± 5.01 |
| Week 100: Swollen Joint Count | 1.8 ± 3.75 | 1.6 ± 3.99 | 2.0 ± 4.11 |
| Week 52: Tender Joint Count | 7.4 ± 10.30 | 6.3 ± 8.20 | 7.2 ± 9.49 |
| Week 68: Tender Joint Count | 6.0 ± 8.83 | 5.0 ± 6.83 | 6.3 ± 9.27 |
| Week 76: Tender Joint Count | 5.7 ± 8.31 | 5.2 ± 7.18 | 6.2 ± 8.90 |
| Week 84: Tender Joint Count | 5.1 ± 7.32 | 4.7 ± 7.20 | 5.9 ± 9.22 |
| Week 100: Tender Joint Count | 5.5 ± 8.44 | 4.7 ± 6.80 | 6.0 ± 8.90 |
| Week 52: Patient's Assessment of Pain | 3.53 ± 2.267 | 3.12 ± 2.335 | 3.17 ± 2.343 |
| Week 68: Patient's Assessment of Pain | 3.26 ± 2.313 | 2.68 ± 2.240 | 2.64 ± 2.105 |
| Week 76: Patient's Assessment of Pain | 3.17 ± 2.271 | 2.73 ± 2.217 | 2.70 ± 2.115 |
| Week 84: Patient's Assessment of Pain | 2.97 ± 2.150 | 2.67 ± 2.181 | 2.65 ± 2.217 |
| Week 100: Patient's Assessment of Pain | 2.90 ± 2.221 | 2.59 ± 2.290 | 2.57 ± 2.138 |
| Week 52: PtGA of Disease Activity | 3.68 ± 2.331 | 3.25 ± 2.380 | 3.24 ± 2.322 |
| Week 68: PtGA of Disease Activity | 3.50 ± 2.355 | 2.95 ± 2.282 | 2.85 ± 2.213 |
| Week 76: PtGA of Disease Activity | 3.25 ± 2.356 | 2.90 ± 2.273 | 2.95 ± 2.222 |
| Week 84: PtGA of Disease Activity | 3.09 ± 2.273 | 2.88 ± 2.252 | 2.83 ± 2.222 |
| Week 100: PtGA of Disease Activity | 3.15 ± 2.395 | 2.85 ± 2.378 | 2.60 ± 2.165 |
| Week 52: PGA of Disease Activity | 1.89 ± 1.654 | 1.78 ± 1.647 | 1.77 ± 1.617 |
| Week 68: PGA of Disease Activity | 1.63 ± 1.514 | 1.56 ± 1.538 | 1.61 ± 1.466 |
| Week 76: PGA of Disease Activity | 1.45 ± 1.469 | 1.67 ± 1.660 | 1.57 ± 1.524 |
| Week 84: PGA of Disease Activity | 1.55 ± 1.492 | 1.51 ± 1.619 | 1.50 ± 1.558 |
| Week 100: PGA of Disease Activity | 1.39 ± 1.510 | 1.49 ± 1.581 | 1.41 ± 1.405 |
| Week 52: HAQ-DI score | 0.9073 ± 0.63812 | 0.7942 ± 0.59711 | 0.7317 ± 0.58430 |
| Week 68: HAQ-DI score | 0.8425 ± 0.61757 | 0.7625 ± 0.59524 | 0.6836 ± 0.56049 |
| Week 76: HAQ-DI score | 0.8311 ± 0.62101 | 0.6978 ± 0.56588 | 0.6996 ± 0.55988 |
| Week 84: HAQ-DI score | 0.8076 ± 0.62465 | 0.7134 ± 0.59528 | 0.6775 ± 0.58870 |
| Week 100: HAQ-DI score | 0.7692 ± 0.59960 | 0.6747 ± 0.57213 | 0.6420 ± 0.56838 |
| Week 52: CRP | 0.904 ± 1.6039 | 0.930 ± 1.2443 | 0.886 ± 1.2366 |
| Week 68: CRP | 0.861 ± 1.1586 | 0.884 ± 1.3520 | 0.796 ± 1.1109 |
| Week 76: CRP | 0.903 ± 1.4624 | 0.882 ± 1.2504 | 0.839 ± 1.1693 |
| Week 84: CRP | 0.898 ± 1.3229 | 0.856 ± 1.1926 | 0.872 ± 1.3239 |
| Week 100: CRP | 0.880 ± 1.3415 | 0.826 ± 1.2277 | 0.820 ± 1.1227 |
ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52: Swollen Joint Count | -10.2 ± 6.72 | -9.6 ± 6.30 | -10.4 ± 6.16 |
| Week 68: Swollen Joint Count | -10.7 ± 6.76 | -10.0 ± 6.50 | -10.9 ± 7.22 |
| Week 76: Swollen Joint Count | -10.7 ± 5.98 | -10.0 ± 6.33 | -10.7 ± 6.18 |
| Week 84: Swollen Joint Count | -10.6 ± 6.06 | -10.1 ± 6.34 | -10.7 ± 7.08 |
| Week 100: Swollen Joint Count | -10.6 ± 6.15 | -10.2 ± 6.88 | -10.8 ± 6.66 |
| Week 52: Tender Joint Count | -14.1 ± 11.38 | -13.5 ± 10.04 | -15.2 ± 10.45 |
| Week 68: Tender Joint Count | -15.7 ± 10.94 | -14.8 ± 10.15 | -16.0 ± 11.02 |
| Week 76: Tender Joint Count | -16.1 ± 10.97 | -14.7 ± 10.22 | -16.1 ± 10.91 |
| Week 84: Tender Joint Count | -16.6 ± 11.33 | -15.3 ± 10.50 | -16.0 ± 11.22 |
| Week 100: Tender Joint Count | -16.3 ± 11.27 | -15.3 ± 11.10 | -16.4 ± 10.70 |
| Week 52: Patient's Assessment of Pain | -2.78 ± 2.645 | -3.20 ± 2.557 | -2.92 ± 2.686 |
| Week 68: Patient's Assessment of Pain | -3.10 ± 2.707 | -3.62 ± 2.530 | -3.46 ± 2.574 |
| Week 76: Patient's Assessment of Pain | -3.18 ± 2.724 | -3.57 ± 2.566 | -3.38 ± 2.620 |
| Week 84: Patient's Assessment of Pain | -3.35 ± 2.595 | -3.64 ± 2.568 | -3.42 ± 2.669 |
| Week 100: Patient's Assessment of Pain | -3.41 ± 2.578 | -3.69 ± 2.625 | -3.52 ± 2.615 |
| Week 52: PtGA of Disease Activity | -2.87 ± 2.761 | -3.29 ± 2.553 | -3.09 ± 2.523 |
| Week 68: PtGA of Disease Activity | -3.08 ± 2.786 | -3.58 ± 2.446 | -3.49 ± 2.500 |
| Week 76: PtGA of Disease Activity | -3.32 ± 2.860 | -3.63 ± 2.512 | -3.38 ± 2.501 |
| Week 84: PtGA of Disease Activity | -3.46 ± 2.752 | -3.67 ± 2.572 | -3.50 ± 2.579 |
| Week 100: PtGA of Disease Activity | -3.40 ± 2.846 | -3.67 ± 2.612 | -3.73 ± 2.493 |
| Week 52: PGA of Disease Activity | -4.79 ± 1.992 | -4.77 ± 2.001 | -4.82 ± 2.117 |
| Week 68: PGA of Disease Activity | -5.06 ± 2.037 | -4.98 ± 1.992 | -5.01 ± 2.105 |
| Week 76: PGA of Disease Activity | -5.23 ± 1.995 | -4.86 ± 2.044 | -5.03 ± 2.078 |
| Week 84: PGA of Disease Activity | -5.13 ± 2.040 | -5.06 ± 2.074 | -5.09 ± 2.142 |
| Week 100: PGA of Disease Activity | -5.26 ± 2.098 | -5.05 ± 2.011 | -5.18 ± 2.044 |
| Week 52: HAQ-DI score | -0.3899 ± 0.58250 | -0.4801 ± 0.56246 | -0.5111 ± 0.58347 |
| Week 68: HAQ-DI score | -0.4668 ± 0.59226 | -0.5120 ± 0.54928 | -0.5631 ± 0.54528 |
| Week 76: HAQ-DI score | -0.4740 ± 0.57852 | -0.5694 ± 0.56421 | -0.5448 ± 0.54739 |
| Week 84: HAQ-DI score | -0.5041 ± 0.59716 | -0.5653 ± 0.59488 | -0.5656 ± 0.57921 |
| Week 100: HAQ-DI score | -0.5356 ± 0.56707 | -0.5859 ± 0.58199 | -0.6000 ± 0.56858 |
| Week 52: CRP | -1.262 ± 2.8315 | -1.021 ± 2.2301 | -0.959 ± 2.4188 |
| Week 68: CRP | -1.212 ± 2.3061 | -1.081 ± 2.1585 | -1.060 ± 2.3334 |
| Week 76: CRP | -1.283 ± 2.8163 | -1.098 ± 2.3654 | -1.017 ± 2.2801 |
| Week 84: CRP | -1.230 ± 2.4262 | -1.101 ± 2.1216 | -0.940 ± 2.3781 |
| Week 100: CRP | -1.244 ± 2.5828 | -1.129 ± 2.2261 | -1.042 ± 2.0600 |
ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).
| percent change | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52: Swollen Joint Count | -82.64 ± 30.161 | -83.03 ± 30.210 | -84.27 ± 23.698 |
| Week 68: Swollen Joint Count | -87.41 ± 24.049 | -86.08 ± 29.764 | -86.41 ± 22.642 |
| Week 76: Swollen Joint Count | -87.98 ± 20.617 | -86.05 ± 21.096 | -85.82 ± 22.291 |
| Week 84: Swollen Joint Count | -87.72 ± 22.243 | -87.68 ± 23.304 | -87.16 ± 24.888 |
| Week 100: Swollen Joint Count | -87.61 ± 21.214 | -86.19 ± 40.865 | -86.31 ± 24.106 |
| Week 52: Tender Joint Count | -67.29 ± 35.725 | -70.18 ± 32.062 | -70.54 ± 31.311 |
| Week 68: Tender Joint Count | -74.28 ± 29.764 | -75.63 ± 29.437 | -74.40 ± 29.760 |
| Week 76: Tender Joint Count | -75.71 ± 27.653 | -74.71 ± 29.728 | -75.11 ± 28.559 |
| Week 84: Tender Joint Count | -77.21 ± 27.045 | -78.01 ± 26.112 | -75.45 ± 32.489 |
| Week 100: Tender Joint Count | -77.04 ± 27.510 | -75.96 ± 32.600 | -76.21 ± 27.345 |
| Week 52: Patient's Assessment of Pain | -39.52 ± 44.939 | -48.81 ± 39.191 | -43.86 ± 45.891 |
| Week 68: Patient's Assessment of Pain | -44.91 ± 44.371 | -55.77 ± 38.780 | -52.43 ± 41.186 |
| Week 76: Patient's Assessment of Pain | -46.02 ± 44.989 | -54.38 ± 39.135 | -51.34 ± 41.903 |
| Week 84: Patient's Assessment of Pain | -49.64 ± 40.991 | -55.28 ± 40.388 | -52.59 ± 43.131 |
| Week 100: Patient's Assessment of Pain | -50.82 ± 42.970 | -56.36 ± 41.310 | -54.27 ± 40.819 |
| Week 52: PtGA of Disease Activity | -39.70 ± 44.981 | -48.48 ± 38.982 | -46.07 ± 40.614 |
| Week 68: PtGA of Disease Activity | -42.93 ± 44.220 | -53.84 ± 35.096 | -52.47 ± 38.155 |
| Week 76: PtGA of Disease Activity | -46.42 ± 45.106 | -54.41 ± 35.276 | -50.66 ± 40.992 |
| Week 84: PtGA of Disease Activity | -49.38 ± 42.315 | -54.17 ± 37.132 | -51.86 ± 44.532 |
| Week 100: PtGA of Disease Activity | -48.17 ± 44.804 | -55.08 ± 37.052 | -57.09 ± 34.970 |
| Week 52: PGA of Disease Activity | -71.24 ± 24.771 | -72.95 ± 24.168 | -72.58 ± 24.579 |
| Week 68: PGA of Disease Activity | -74.76 ± 23.290 | -76.00 ± 22.550 | -74.48 ± 26.280 |
| Week 76: PGA of Disease Activity | -77.68 ± 23.015 | -74.42 ± 25.014 | -75.56 ± 23.613 |
| Week 84: PGA of Disease Activity | -75.77 ± 23.674 | -76.77 ± 24.433 | -76.49 ± 24.355 |
| Week 100: PGA of Disease Activity | -78.11 ± 24.049 | -77.15 ± 23.217 | -77.82 ± 22.733 |
| Week 52: HAQ-DI score | -27.27 ± 54.587 | -33.28 ± 64.067 | -35.17 ± 66.105 |
| Week 68: HAQ-DI score | -33.34 ± 49.027 | -37.47 ± 57.370 | -44.33 ± 44.064 |
| Week 76: HAQ-DI score | -34.38 ± 47.311 | -40.08 ± 58.932 | -41.84 ± 47.877 |
| Week 84: HAQ-DI score | -36.73 ± 47.541 | -40.10 ± 58.703 | -43.18 ± 52.116 |
| Week 100: HAQ-DI score | -40.36 ± 44.407 | -42.84 ± 54.187 | -47.54 ± 47.265 |
| Week 52: CRP | -2.67 ± 205.761 | -23.41 ± 104.622 | -1.34 ± 194.673 |
| Week 68: CRP | -1.68 ± 330.574 | -28.38 ± 138.159 | -13.91 ± 174.522 |
| Week 76: CRP | -10.76 ± 226.332 | 7.85 ± 502.170 | -24.22 ± 110.486 |
| Week 84: CRP | -0.72 ± 387.986 | -26.87 ± 114.471 | -19.89 ± 131.695 |
| Week 100: CRP | -4.33 ± 196.246 | -23.99 ± 150.816 | -14.35 ± 171.666 |
ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Who Maintained an ACR 20 Response at Week 100 Among Participants Who Achieved an ACR 20 Response at Week 52 | 94.6 | 90.4 | 93.0 |
ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Who Maintained an ACR 50 Response at Week 100 Among Participants Who Achieved an ACR 50 Response at Week 52 | 81.3 | 81.9 | 83.8 |
ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 millimeters \[mm\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Who Maintained an ACR 70 Response at Week 100 Among Participants Who Achieved an ACR 70 Response at Week 52 | 65.1 | 80.9 | 71.9 |
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | -0.3899 ± 0.58250 | -0.4801 ± 0.56246 | -0.5111 ± 0.58347 |
| Week 68 | -0.4668 ± 0.59226 | -0.5120 ± 0.54928 | -0.5631 ± 0.54528 |
| Week 76 | -0.4740 ± 0.57852 | -0.5694 ± 0.56421 | -0.5448 ± 0.54739 |
| Week 84 | -0.5041 ± 0.59716 | -0.5653 ± 0.59488 | -0.5656 ± 0.57921 |
| Week 100 | -0.5356 ± 0.56707 | -0.5859 ± 0.58199 | -0.6000 ± 0.56858 |
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 51.1 | 60.6 | 63.3 |
| Week 68 | 57.2 | 64.9 | 69.4 |
| Week 76 | 59.3 | 68.4 | 64.7 |
| Week 84 | 58.9 | 66.8 | 65.5 |
| Week 100 | 63.3 | 70.7 | 70.1 |
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 100 Among Participants Who Achieved a HAQ-DI Response at Week 52 | 91.6 | 90.4 | 88.5 |
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS28 (CRP) response criteria was defined as follows: Good response: \<=3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder was defined as achieving a good or moderate DAS28 response at a specific visit.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 89.3 | 89.7 | 90.2 |
| Week 68 | 92.7 | 92.5 | 92.7 |
| Week 76 | 94.1 | 90.2 | 93.3 |
| Week 84 | 94.8 | 92.7 | 92.5 |
| Week 100 | 94.3 | 90.6 | 92.7 |
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS28 (CRP) remission was defined as DAS28 (CRP) value \<2.6 at the analysis visit.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 34.7 | 39.7 | 40.4 |
| Week 68 | 39.0 | 44.9 | 49.1 |
| Week 76 | 43.2 | 44.2 | 43.5 |
| Week 84 | 41.8 | 50.9 | 48.1 |
| Week 100 | 42.4 | 47.5 | 51.6 |
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | -2.14 ± 1.142 | -2.08 ± 1.124 | -2.14 ± 1.118 |
| Week 68 | -2.29 ± 1.132 | -2.25 ± 1.170 | -2.30 ± 1.143 |
| Week 76 | -2.35 ± 1.110 | -2.24 ± 1.147 | -2.24 ± 1.087 |
| Week 84 | -2.40 ± 1.087 | -2.35 ± 1.181 | -2.31 ± 1.156 |
| Week 100 | -2.42 ± 1.144 | -2.37 ± 1.215 | -2.36 ± 1.120 |
The modified PsARC response was defined as improvement in at least 2 of the four criteria: \>=30% decrease in swollen joint count, \>=30% decrease in tender joint count, \>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) on a VAS (0-100 mm, 0=excellent and 100= poor), \>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 81.4 | 86.2 | 83.6 |
| Week 68 | 84.3 | 89.9 | 87.6 |
| Week 76 | 84.6 | 88.8 | 90.6 |
| Week 84 | 87.4 | 87.7 | 87.6 |
| Week 100 | 86.3 | 89.3 | 88.6 |
Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 67.3 | 66.0 | 61.0 |
| Week 76 | 72.3 | 71.8 | 67.5 |
| Week 100 | 75.2 | 77.5 | 67.7 |
Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | -2.1 ± 1.59 | -1.9 ± 1.66 | -2.1 ± 1.72 |
| Week 76 | -2.3 ± 1.52 | -2.1 ± 1.66 | -2.2 ± 1.69 |
| Week 100 | -2.4 ± 1.70 | -2.1 ± 1.65 | -2.2 ± 1.80 |
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 78.3 | 81.7 | 80.7 |
| Week 76 | 80.2 | 84.0 | 82.4 |
| Week 100 | 83.7 | 91.1 | 82.9 |
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement of dactylitis.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | -7.4 ± 9.22 | -7.3 ± 9.78 | -7.4 ± 8.66 |
| Week 76 | -8.0 ± 9.55 | -7.8 ± 10.24 | -7.6 ± 8.93 |
| Week 100 | -8.1 ± 9.63 | -7.9 ± 10.12 | -7.9 ± 9.14 |
PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | -3.054 ± 1.4954 | -3.189 ± 1.5216 | -3.184 ± 1.4576 |
| Week 76 | -3.503 ± 1.4708 | -3.418 ± 1.5646 | -3.436 ± 1.4428 |
| Week 100 | -3.574 ± 1.4785 | -3.586 ± 1.5425 | -3.549 ± 1.4635 |
PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining PtGA of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), PGA of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity. Low: PASDAS \<= 3.2; Very low: PASDAS \<= 1.9.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52: Low | 39.0 | 44.8 | 46.7 |
| Week 52: Very Low | 13.0 | 22.0 | 16.0 |
| Week 76: Low | 52.1 | 50.0 | 49.8 |
| Week 76: Very Low | 18.3 | 23.4 | 22.0 |
| Week 100: Low | 55.3 | 54.7 | 57.8 |
| Week 100: Very Low | 19.9 | 26.0 | 23.4 |
GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\*HAQ-DI\]-\[0.234\*SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0-100, higher scores= better quality of life) and SF-MCS (score ranges from 0-100, higher scores= better quality of life). Total score is from 0-10, lower score=better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | -3.105 ± 1.6208 | -3.266 ± 1.6443 | -3.298 ± 1.5457 |
| Week 76 | -3.499 ± 1.6303 | -3.528 ± 1.5778 | -3.541 ± 1.5048 |
| Week 100 | -3.561 ± 1.6389 | -3.656 ± 1.6071 | -3.664 ± 1.5205 |
GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), PtGA of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), PtGA of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\*HAQ-DI\]-\[0.234\*SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score range= 0-100, higher scores= better quality of life) and SF-MCS (score range=0-100, higher scores= better quality of life). Total score is 0-10, lower score=better response. Higher score= more active disease activity. Negative change from baseline indicates improvement of PsA disease activity. GRACE low disease activity is GRACE score \<=2.3 at the analysis visit.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 35.4 | 42.7 | 43.8 |
| Week 76 | 45.7 | 48.9 | 49.8 |
| Week 100 | 48.1 | 51.1 | 54.5 |
DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL, value \<lower limit of quantification \[LLOQ\] is considered equal to half of the value of LLOQ for numerical calculations), patient assessment of pain (0-10cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | -31.274 ± 18.8900 | -30.604 ± 17.5366 | -32.563 ± 16.4765 |
| Week 68 | -33.918 ± 18.0463 | -33.146 ± 18.1727 | -34.900 ± 17.5749 |
| Week 76 | -34.391 ± 17.4074 | -33.062 ± 17.5186 | -34.590 ± 16.5401 |
| Week 84 | -35.240 ± 17.7891 | -33.622 ± 18.0612 | -34.570 ± 18.2685 |
| Week 100 | -34.819 ± 17.9807 | -34.019 ± 19.2678 | -35.549 ± 16.5533 |
DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL), patient assessment of pain (0-10 cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10 cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. The assessment does not have a score range with an upper or lower bound. Low: DAPSA\<=14; Remission: DAPSA\<=4.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52: Low Disease Activity | 50.7 | 55.2 | 55.6 |
| Week 52: Remission | 10.2 | 19.4 | 17.3 |
| Week 68: Low Disease Activity | 54.1 | 64.3 | 63.3 |
| Week 68: Remission | 15.6 | 23.8 | 23.9 |
| Week 76: Low Disease Activity | 58.2 | 61.2 | 61.4 |
| Week 76: Remission | 16.4 | 26.8 | 19.7 |
| Week 84: Low Disease Activity | 60.6 | 66.5 | 64.6 |
| Week 84: Remission | 17.8 | 28.0 | 23.6 |
| Week 100: Low Disease Activity | 61.9 | 65.9 | 68.9 |
| Week 100: Remission | 18.6 | 26.9 | 23.7 |
The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | -3.78 ± 2.392 | -3.83 ± 2.458 | -4.14 ± 2.358 |
| Week 76 | -4.39 ± 2.425 | -4.16 ± 2.539 | -4.47 ± 2.347 |
| Week 100 | -4.44 ± 2.484 | -4.38 ± 2.433 | -4.52 ± 2.519 |
The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. mCPDAI low disease activity is defined as mCPDAI score \<=3.2 at the analysis visit.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 56.6 | 61.2 | 60.6 |
| Week 76 | 64.3 | 63.7 | 68.6 |
| Week 100 | 67.5 | 71.7 | 68.0 |
MDA is a measure that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved the PsA MDA at a visit if the participant has fulfilled at least 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI index score \<= 1).
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 32.0 | 32.8 | 37.2 |
| Week 76 | 34.7 | 40.0 | 39.0 |
| Week 100 | 42.5 | 44.6 | 42.7 |
A measurement that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved VLDA at a visit if the participant fulfilled all 7 criteria (tender joint count \<=1; swollen joint count \<=1; PASI \<=1; patient pain VAS score of \<=15; patient global disease activity VAS \[arthritis and psoriasis\] score of \<=20; Health Assessment Questionnaire (HAQ) score \<=0.5; and tender entheseal points \<=1) at that visit.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 7.0 | 16.8 | 12.4 |
| Week 76 | 12.2 | 19.6 | 14.8 |
| Week 100 | 14.6 | 18.8 | 15.0 |
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | -2.986 ± 2.4945 | -2.923 ± 2.5194 | -3.084 ± 2.1843 |
| Week 76 | -3.311 ± 2.6106 | -3.377 ± 2.5969 | -3.129 ± 2.1122 |
| Week 100 | -3.718 ± 2.3960 | -3.472 ± 2.5233 | -3.330 ± 2.1598 |
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52: Participants with >=20% Improvement | 71.6 | 69.8 | 79.7 |
| Week 76: Participants with >=20% Improvement | 74.1 | 82.0 | 81.8 |
| Week 100: Participants with >=20% Improvement | 87.8 | 77.0 | 82.9 |
| Week 52: Participants with >=50% Improvement | 50.0 | 42.9 | 50.6 |
| Week 76: Participants with >=50% Improvement | 52.9 | 52.5 | 50.6 |
| Week 100: Participants with >=50% Improvement | 59.8 | 57.4 | 55.3 |
| Week 52: Participants with >=70% Improvement | 23.9 | 27.0 | 30.4 |
| Week 76: Participants with >=70% Improvement | 31.8 | 31.1 | 26.0 |
| Week 100: Participants with >=70% Improvement | 32.9 | 39.3 | 32.9 |
| Week 52: Participants with >=90% Improvement | 6.8 | 11.1 | 8.9 |
| Week 76: Participants with >=90% Improvement | 11.8 | 13.1 | 7.8 |
| Week 100: Participants with >=90% Improvement | 18.3 | 11.5 | 9.2 |
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative change from baseline indicates improvement of psoriasis.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | -11.030 ± 10.0077 | -11.991 ± 12.1194 | -12.875 ± 11.2905 |
| Week 76 | -11.313 ± 10.0631 | -11.991 ± 12.2656 | -13.242 ± 11.8845 |
| Week 100 | -11.089 ± 10.0239 | -12.101 ± 12.1322 | -13.274 ± 11.9673 |
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 50 response: \>=50% improvement in PASI score from baseline.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 95.9 | 97.0 | 98.3 |
| Week 76 | 97.6 | 96.4 | 97.1 |
| Week 100 | 95.6 | 97.0 | 98.2 |
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 88.3 | 88.8 | 91.9 |
| Week 76 | 92.8 | 87.9 | 93.0 |
| Week 100 | 91.9 | 87.8 | 89.4 |
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 90 response: \>=90% improvement in PASI score from baseline.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 76.6 | 76.9 | 81.5 |
| Week 76 | 85.5 | 75.8 | 80.2 |
| Week 100 | 87.5 | 75.0 | 80.0 |
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 100 response: 100% improvement in PASI score from baseline.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 55.0 | 54.4 | 60.7 |
| Week 76 | 65.1 | 59.4 | 68.0 |
| Week 100 | 69.4 | 57.3 | 64.1 |
In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in swollen joint count (SJC) (66 joints) + tender joint count (TJC) (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 59.4 | 73.4 | 70.5 |
| Week 76 | 71.1 | 75.8 | 76.7 |
| Week 100 | 73.0 | 76.1 | 77.5 |
In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 70.8 | 79.3 | 76.9 |
| Week 76 | 78.3 | 79.4 | 82.6 |
| Week 100 | 78.8 | 81.1 | 78.8 |
A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). IGA Response is defined as achieving IGA score of 0 or 1, and \>=2 grade reduction from baseline.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 84.2 | 76.9 | 84.4 |
| Week 76 | 85.5 | 77.6 | 86.0 |
| Week 100 | 88.1 | 76.4 | 82.4 |
A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 66.7 | 59.8 | 65.9 |
| Week 76 | 72.9 | 64.2 | 72.1 |
| Week 100 | 76.9 | 58.8 | 67.1 |
Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. A DLQI score of 0 or 1 indicates psoriasis had no effect at all on patient's life.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 56.5 | 68.4 | 68.5 |
| Week 76 | 66.9 | 66.7 | 68.9 |
| Week 100 | 74.7 | 69.6 | 64.8 |
Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. An improvement of 5 points was considered clinically meaningful.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 84.8 | 92.2 | 89.4 |
| Week 76 | 91.9 | 89.0 | 90.1 |
| Week 100 | 91.7 | 94.4 | 88.5 |
Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. Negative changes from baseline indicate improvement of life quality impacted by psoriasis.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | -8.855 ± 7.2738 | -9.272 ± 7.3903 | -9.873 ± 6.8832 |
| Week 76 | -10.090 ± 7.0888 | -9.180 ± 7.2977 | -9.610 ± 7.0383 |
| Week 100 | -10.130 ± 7.2798 | -9.291 ± 7.2851 | -9.635 ± 7.0884 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change in Modified vdH-S Score From Baseline to Week 100 | 1.49 ± 6.859 | 1.50 ± 4.393 | 1.68 ± 7.018 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change in Total Modified vdH-S Score From Week 52 to Week 100 | 0.13 ± 3.742 | 0.46 ± 2.419 | 0.75 ± 4.021 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change in Modified vdH-s Erosion Score From Baseline to Week 100 | 1.01 ± 4.034 | 1.01 ± 3.355 | 1.02 ± 4.676 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change in Modified vdH-s Erosion Score From Week 52 to Week 100 | 0.09 ± 1.978 | 0.26 ± 1.751 | 0.45 ± 2.900 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change in Modified vdH-s JSN Score From Baseline to Week 100 | 0.49 ± 2.984 | 0.50 ± 1.387 | 0.66 ± 2.722 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change in Modified vdH-s JSN Score From Week 52 to Week 100 | 0.04 ± 1.904 | 0.20 ± 0.917 | 0.30 ± 1.319 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand (Hand erosion score) scored according to 0 (no erosion) to 5 (complete collapse of bone) for a maximum hand erosion score of 200, and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum foot erosion score of 120. Higher scores indicate more joint damage. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum Hand JSN score of 160 and maximum Foot JSN score of 48. Higher scores indicate more joint damage. Hand Score (sum of Hand Erosion Score and Hand JSN Score) scored as 0-360 and Foot score (sum of foot erosion score and foot JSN score) scored as 0-168. Higher scores indicate more joint damage.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Hand Erosion Score | 0.67 ± 2.917 | 0.67 ± 2.807 | 0.49 ± 3.007 |
| Hand JSN Score | 0.35 ± 2.443 | 0.34 ± 1.247 | 0.32 ± 1.845 |
| Hand Score | 1.02 ± 5.244 | 1.02 ± 3.815 | 0.81 ± 4.532 |
| Foot Erosion Score | 0.34 ± 1.596 | 0.33 ± 1.362 | 0.53 ± 2.436 |
| Foot JSN Score | 0.13 ± 0.912 | 0.15 ± 0.652 | 0.34 ± 1.608 |
| Foot Score | 0.48 ± 2.373 | 0.48 ± 1.652 | 0.87 ± 3.761 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change of <=0 from Baseline | 60.8 | 55.6 | 62.6 |
| Change of <=0.5 from Baseline | 72.1 | 63.9 | 72.5 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change of <=0 from Baseline | 64.2 | 61.1 | 65.4 |
| Change of <=0.5 from Baseline | 75.0 | 73.1 | 75.4 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change of <=0 from Baseline | 77.5 | 68.5 | 73.9 |
| Change of <=0.5 from Baseline | 84.3 | 79.6 | 81.0 |
Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic progression was defined as change from baseline in the modified vdH-S score \<=SDC of 3.46.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Without Radiographic Modified vdH-S Progression Based on (SDC) From Baseline to Week 100 | 86.8 | 84.7 | 87.2 |
Modified vdH-S score is sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic erosion progression was defined as change from baseline in the modified vdH-S erosion score \<=SDC of 2.66.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Without Radiographic Erosion Progression (Based on SDC) From Baseline to Week 100 | 86.8 | 87.0 | 88.6 |
Modified vdH-S score is sum of erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic JSN progression was defined as change from baseline in the modified vdH-S JSN score \<=SDC of 1.66.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Without Radiographic JSN Progression (Based on SDC) From Baseline to Week 100 | 90.7 | 89.4 | 88.2 |
Pencil in Cup or Gross Osteolytis Deformities are radiographic features specific for psoriatic arthritis.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Baseline | 3.7 | 3.9 | 3.6 |
| Week 24 | 3.7 | 3.9 | 4.1 |
| Week 52 | 4.2 | 4.4 | 3.6 |
| Week 100 | 4.9 | 4.6 | 3.8 |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 8.170 ± 8.2195 | 9.438 ± 8.2854 | 9.023 ± 8.6263 |
| Week 76 | 9.762 ± 8.5908 | 10.814 ± 9.0290 | 9.707 ± 8.5010 |
| Week 100 | 10.508 ± 8.6819 | 11.282 ± 9.2753 | 10.559 ± 8.7449 |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 4.383 ± 10.9402 | 4.540 ± 9.7848 | 4.127 ± 9.1368 |
| Week 76 | 4.838 ± 11.0526 | 5.034 ± 10.0334 | 5.194 ± 9.4899 |
| Week 100 | 4.610 ± 11.2527 | 4.718 ± 9.9014 | 4.936 ± 9.5935 |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52: Physical Function Score | 7.757 ± 8.9727 | 8.406 ± 8.8407 | 8.493 ± 8.7691 |
| Week 76: Physical Function Score | 8.824 ± 9.6648 | 9.807 ± 9.5044 | 9.294 ± 8.2020 |
| Week 100: Physical Function Score | 9.738 ± 9.8405 | 10.953 ± 9.7761 | 10.126 ± 8.9271 |
| Week 52: Role-physical Score | 6.538 ± 8.5151 | 7.665 ± 8.2925 | 7.372 ± 7.7581 |
| Week 76: Role-physical Score | 8.372 ± 8.7202 | 9.171 ± 8.5844 | 8.579 ± 7.6709 |
| Week 100: Role-physical Score | 9.181 ± 8.6596 | 9.342 ± 9.1746 | 8.921 ± 8.1775 |
| Week 52: Bodily Pain Score | 8.536 ± 8.4602 | 10.201 ± 8.7312 | 9.525 ± 9.8357 |
| Week 76: Bodily Pain Score | 10.368 ± 9.1058 | 11.552 ± 9.8591 | 10.300 ± 9.0504 |
| Week 100: Bodily Pain Score | 10.696 ± 9.3854 | 11.585 ± 10.3527 | 10.998 ± 8.9230 |
| Week 52: General Health Score | 6.533 ± 8.5245 | 7.097 ± 7.2500 | 6.450 ± 8.4316 |
| Week 76: General Health Score | 7.203 ± 8.3372 | 7.470 ± 7.6119 | 6.761 ± 7.9631 |
| Week 100: General Health Score | 6.710 ± 8.7265 | 7.066 ± 7.5829 | 7.132 ± 8.4887 |
| Week 52: Vitality Score | 7.997 ± 9.3878 | 8.695 ± 9.5033 | 7.637 ± 9.4393 |
| Week 76: Vitality Score | 8.859 ± 9.4372 | 9.388 ± 9.8618 | 8.659 ± 9.6026 |
| Week 100: Vitality Score | 9.648 ± 9.4778 | 9.827 ± 9.9348 | 9.155 ± 9.3569 |
| Week 52: Social Function Score | 6.361 ± 10.9927 | 7.304 ± 10.1003 | 6.810 ± 9.5118 |
| Week 76: Social Function Score | 7.509 ± 10.4249 | 8.623 ± 9.5176 | 7.914 ± 9.5191 |
| Week 100: Social Function Score | 7.825 ± 10.8558 | 8.080 ± 9.5383 | 8.113 ± 9.4847 |
| Week 52: Role-emotional Score | 4.111 ± 10.9413 | 4.998 ± 10.1964 | 4.699 ± 8.7759 |
| Week 76: Role-emotional Score | 5.199 ± 11.1875 | 5.757 ± 10.0737 | 5.433 ± 9.2389 |
| Week 100: Role-emotional Score | 4.784 ± 11.9482 | 5.720 ± 10.1991 | 5.128 ± 9.7998 |
| Week 52: Mental Health Score | 5.209 ± 10.0958 | 4.826 ± 9.4038 | 4.839 ± 9.4029 |
| Week 76: Mental Health Score | 5.481 ± 10.5927 | 5.430 ± 10.0802 | 6.124 ± 8.7930 |
| Week 100: Mental Health Score | 5.514 ± 10.6204 | 5.477 ± 10.1202 | 6.148 ± 8.8743 |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 63.4 | 66.8 | 65.9 |
| Week 76 | 70.6 | 73.8 | 65.5 |
| Week 100 | 72.4 | 70.1 | 68.6 |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 42.3 | 45.3 | 38.9 |
| Week 76 | 43.9 | 44.4 | 43.5 |
| Week 100 | 42.1 | 46.4 | 43.6 |
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 7.692 ± 9.3071 | 8.935 ± 9.5033 | 7.699 ± 9.1417 |
| Week 76 | 9.167 ± 9.0455 | 9.596 ± 10.4788 | 8.632 ± 8.8429 |
| Week 100 | 9.435 ± 9.4513 | 10.107 ± 10.2076 | 9.127 ± 8.9948 |
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
| percentage of participants | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 68.7 | 69.4 | 68.1 |
| Week 76 | 70.6 | 69.3 | 74.4 |
| Week 100 | 72.0 | 72.8 | 74.1 |
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a vertical line VAS with scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). A higher score indicates better health and positive changes from baseline indicate improvement of health status.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 21.608 ± 25.5992 | 23.392 ± 23.6990 | 20.190 ± 24.8348 |
| Week 76 | 24.176 ± 27.7205 | 25.053 ± 26.0372 | 22.251 ± 24.6934 |
| Week 100 | 25.901 ± 28.4028 | 27.152 ± 26.5221 | 25.909 ± 26.0995 |
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a weighted summary index (EQ-5D index), which ranges from 0 (dead) to 1.00 (full health). A higher score indicates better health and positive changes from baseline indicate improvement of health.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | 0.138 ± 0.1608 | 0.150 ± 0.1445 | 0.138 ± 0.1458 |
| Week 76 | 0.154 ± 0.1744 | 0.169 ± 0.1564 | 0.147 ± 0.1471 |
| Week 100 | 0.164 ± 0.1605 | 0.164 ± 0.1596 | 0.156 ± 0.1543 |
Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | -5.45 ± 25.544 | -4.50 ± 20.530 | -1.83 ± 17.191 |
| Week 76 | -5.92 ± 26.032 | -6.22 ± 23.133 | -2.39 ± 19.277 |
| Week 100 | -8.81 ± 24.313 | -5.81 ± 21.606 | -1.56 ± 16.956 |
Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | -21.81 ± 31.391 | -27.93 ± 25.263 | -22.62 ± 26.058 |
| Week 76 | -26.90 ± 28.965 | -29.91 ± 24.549 | -26.13 ± 25.412 |
| Week 100 | -30.73 ± 30.933 | -30.65 ± 24.771 | -27.77 ± 26.119 |
Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | -22.61 ± 31.979 | -28.19 ± 25.536 | -22.79 ± 26.793 |
| Week 76 | -27.98 ± 29.709 | -30.27 ± 26.058 | -26.21 ± 28.115 |
| Week 100 | -31.87 ± 31.013 | -31.75 ± 25.615 | -25.21 ± 26.317 |
Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
| units on a scale | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 52 | -24.67 ± 27.106 | -27.16 ± 25.662 | -26.24 ± 25.113 |
| Week 76 | -28.05 ± 26.411 | -31.38 ± 25.449 | -28.70 ± 24.635 |
| Week 100 | -30.70 ± 28.632 | -30.98 ± 26.650 | -30.68 ± 25.305 |
Collected over From baseline after the first administration of study drug through End of Study (up to Week 112). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (CP) | 0/246 (0%) | 7/246 (2.8%) | 30/246 (12.2%) |
| Guselkumab 100 mg q8w (CP) | 0/248 (0%) | 3/248 (1.2%) | 42/248 (16.9%) |
| Guselkumab 100 mg q4w (CP) | 0/245 (0%) | 8/245 (3.3%) | 52/245 (21.2%) |
| Placebo to Guselkumab 100 mg q4w (After CP Through Week 112) | 1/238 (0.4%) | 16/238 (6.7%) | 48/238 (20.2%) |
| Guselkumab 100 mg q8w (Through Week 112) | 0/248 (0%) | 22/248 (8.9%) | 88/248 (35.5%) |
| Guselkumab 100 mg q4w (Through Week 112) | 0/245 (0%) | 22/245 (9%) | 79/245 (32.2%) |
| Event | Placebo (CP) | Guselkumab 100 mg q8w (CP) | Guselkumab 100 mg q4w (CP) | Placebo to Guselkumab 100 mg q4w (After CP Through Week 112) | Guselkumab 100 mg q8w (Through Week 112) | Guselkumab 100 mg q4w (Through Week 112) |
|---|---|---|---|---|---|---|
| Ankle FractureInjury, poisoning and procedural complications | 0/246 | 1/248 | 0/245 | 0/238 | 3/248 | 1/245 |
| GoitreEndocrine disorders | 0/246 | 0/248 | 0/245 | 2/238 | 0/248 | 0/245 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/246 | 0/248 | 1/245 | 2/238 | 0/248 | 2/245 |
| Ischaemic StrokeNervous system disorders | 0/246 | 0/248 | 1/245 | 0/238 | 0/248 | 2/245 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 0/246 | 0/248 | 0/245 | 0/238 | 0/248 | 2/245 |
| Cholecystitis ChronicHepatobiliary disorders | 0/246 | 0/248 | 0/245 | 0/238 | 2/248 | 0/245 |
| PneumoniaInfections and infestations | 0/246 | 0/248 | 0/245 | 1/238 | 2/248 | 1/245 |
| PericarditisCardiac disorders | 0/246 | 0/248 | 0/245 | 1/238 | 0/248 | 0/245 |
| CholelithiasisHepatobiliary disorders | 0/246 | 0/248 | 0/245 | 1/238 | 0/248 | 0/245 |
| Acute Hepatitis CInfections and infestations | 0/246 | 0/248 | 0/245 | 1/238 | 0/248 | 0/245 |
| Event | Placebo (CP) | Guselkumab 100 mg q8w (CP) | Guselkumab 100 mg q4w (CP) | Placebo to Guselkumab 100 mg q4w (After CP Through Week 112) | Guselkumab 100 mg q8w (Through Week 112) | Guselkumab 100 mg q4w (Through Week 112) |
|---|---|---|---|---|---|---|
| Alanine Aminotransferase IncreasedInvestigations | 11/246 | 15/248 | 22/245 | 11/238 | 29/248 | 31/245 |
| NasopharyngitisInfections and infestations | 9/246 | 10/248 | 12/245 | 9/238 | 25/248 | 21/245 |
| Upper Respiratory Tract InfectionInfections and infestations | 8/246 | 7/248 | 13/245 | 18/238 | 24/248 | 20/245 |
| Aspartate Aminotransferase IncreasedInvestigations | 6/246 | 14/248 | 11/245 | 10/238 | 23/248 | 23/245 |
| HeadacheNervous system disorders | 2/246 | 6/248 | 3/245 | 7/238 | 16/248 | 7/245 |
| BronchitisInfections and infestations | 3/246 | 1/248 | 10/245 | 7/238 | 10/248 | 15/245 |
| Age, Continuous(years) | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w | Total |
|---|---|---|---|---|
| Mean | 46.3 ± 11.68 | 44.9 ± 11.89 | 45.9 ± 11.47 | 45.7 ± 11.68 |
| Sex: Female, Male(Participants) | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w | Total |
|---|---|---|---|---|
| Female | 129 | 119 | 103 | 351 |
| Male | 117 | 129 | 142 | 388 |
| Ethnicity (NIH/OMB)(Participants) | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 0 | 2 |
| Not Hispanic or Latino | 245 | 247 | 245 | 737 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 4 | 8 | 3 | 15 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 242 | 240 | 242 | 724 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Placebo to Guselkumab 100 mg q4w | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w | Total |
|---|---|---|---|---|
| BULGARIA | 14 | 9 | 6 | 29 |
| CZECH REPUBLIC | 13 | 5 | 15 | 33 |
| ESTONIA | 5 | 8 | 5 | 18 |
| LATVIA | 3 | 3 | 0 | 6 |
| LITHUANIA | 8 | 8 | 4 | 20 |
| MALAYSIA | 3 | 6 | 3 | 12 |
| POLAND | 35 | 27 | 23 | 85 |
| RUSSIAN FEDERATION | 92 | 77 | 104 | 273 |
| SPAIN | 3 | 12 | 4 | 19 |
| TAIWAN | 0 | 1 | 0 | 1 |
| TURKEY | 2 | 8 | 6 | 16 |
| UKRAINE | 65 | 83 | 73 | 221 |
| UNITED STATES | 3 | 1 | 2 | 6 |
Showing the first 100 of 138 sites across 13 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2017 to primary completion in Feb 2019, 19 months.
Results were first posted in Nov 2020, 1 year 8 months after primary completion. A results delay was requested in Feb 2020.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 19 months is below that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Guselkumab
Janssen Research & Development, LLC →